HK1262960B - Compositions for treatment of retinitis pigmentosa 13 - Google Patents

Description

The present invention related to pharmaceutical compositions comprising antisense oligonucleotides (ASOs) and to pharmaceutical compositions for use in treating Retinitis Pigmentosa 13 (RP13).

BACKGROUND OF THE INVENTION

Retinitis pigmentosa (RP) describes a group of diseases that have similar clinical phenotypes and are associated with genetically heterogeneous causes. RP frequently manifests as a loss of night vision, and can progress to peripheral blindness, resulting in tunnel vision. As the disorder progresses, subjects may lose a significant portion of their photoreceptors before experiencing loss of visual acuity, and can eventually experience complete blindness. RP-associated genes PRPF3, PRPF8, PRPF31, and PAP1 are involved in the assembly of spliceosomes. Although the functional properties of several RP-associated genes have been extensively studied, genotype-phenotype correlations are incompletely understood. However, it is known that disease-causing mutations in the PRPF3, PRPF8, PRPF31 and PAP1 genes have a dominant pattern of inheritance (Berger et al., 2010, Progress in Retinal Eye Research 29, 335-375).

SUMMARY

The invention is defined by the appended claims. The present invention relates to pharmaceutical compositions comprising ASOs as set out in the claims and to pharmaceutical compositions for use in treating retinitis pigmentosa as set out in the claims. Other material disclosed herein is for the assistance of the skilled person in understanding and practicing the invention. For the avoidance of doubt it is noted that the invention herein does not extend to methods of treatment of the human body. Also for the avoidance of doubt it is noted that the invention herein does not extend to the use of pharmaceutical compositions for the treatment of Retinitis pigmentosa 18 (RP18). Disclosed herein are methods of treating Retinitis Pigmentosa 18 (RP18) or Retinitis Pigmentosa 13 (RP13) in a subject in need thereof, by increasing the expression of a target protein or functional RNA by cells of the subject, wherein the cells have a retained-intron-containing pre-mRNA (RIC pre-mRNA), the RIC pre-mRNA comprising a retained intron, an exon flanking the 5' splice site, an exon flanking the 3' splice site, and wherein the RIC pre-mRNA encodes the target protein or functional RNA, the method comprising contacting the cells of the subject with an antisense oligomer (ASO) complementary to a targeted portion of the RIC pre-mRNA encoding the target protein or functional RNA, whereby the retained intron is constitutively spliced from the RIC pre-mRNA encoding the target protein or functional RNA, thereby increasing the level of mRNA encoding the target protein or functional RNA, and increasing the expression of the target protein or functional RNA in the cells of the subject.

Also disclosed herein are methods of increasing expression of a target protein, wherein the target protein is PRPF3 or PRPF8, by cells having a retained-intron-containing pre-mRNA (RIC pre-mRNA), the RIC pre-mRNA comprising a retained intron, an exon flanking the 5' splice site of the retained intron, an exon flanking the 3' splice site of the retained intron, and wherein the RIC pre-mRNA encodes PRPF3 or PRPF8protein, the method comprising contacting the cells with an antisense oligomer (ASO) complementary to a targeted portion of the RIC pre-mRNA encoding PRPF3 or PRPF8 protein, whereby the retained intron is constitutively spliced from the RIC pre-mRNA encoding PRPF3 or PRPF8 protein, thereby increasing the level of mRNA encoding PRPF3 or PRPF8 protein, and increasing the expression of PRPF3 or PRPF8 protein in the cells.

In some cases of any of the aforementioned methods, when the method is a method of treating RP18 the target protein is PRPF3. In some cases of any of the aforementioned methods, when the method is a method of treating RP13 the target protein is PRPF8. In some cases, the target protein or the functional RNA is a compensating protein or a compensating functional RNA that functionally augments or replaces a target protein or functional RNA that is deficient in amount or activity in the subject. In some cases, the cells are in or from a subject having a condition caused by a deficient amount or activity of PRPF3 or PRPF8 protein.

In some cases of any of the aforementioned methods, the deficient amount of the target protein is caused by haploinsufficiency of the target protein, wherein the subject has a first allele encoding a functional target protein, and a second allele from which the target protein is not produced, or a second allele encoding a nonfunctional target protein, and wherein the antisense oligomer binds to a targeted portion of a RIC pre-mRNA transcribed from the first allele. In some cases, the subject has a condition caused by a disorder resulting from a deficiency in the amount or function of the target protein, wherein the subject has (a) a first mutant allele from which (i) the target protein is produced at a reduced level compared to production from a wild-type allele, (ii) the target protein is produced in a form having reduced function compared to an equivalent wild-type protein, or (iii) the target protein is not produced, and (b) a second mutant allele from which (i) the target protein is produced at a reduced level compared to production from a wild-type allele, (ii) the target protein is produced in a form having reduced function compared to an equivalent wild-type protein, or (iii) the target protein is not produced, and wherein when the subject has a first mutant allele a(iii), the second mutant allele is b(i) or b(ii), and wherein when the subject has a second mutant allele b(iii), the first mutant allele is a(i) or a(ii), and wherein the RIC pre-mRNA is transcribed from either the first mutant allele that is a(i) or a(ii), and/or the second allele that is b(i) or b(ii). In some cases, the target protein is produced in a form having reduced function compared to the equivalent wild-type protein. In some cases, the target protein is produced in a form that is fully-functional compared to the equivalent wild-type protein.

In some cases of any of the aforementioned methods, the targeted portion of the RIC pre-mRNA is in the retained intron within the region +6 relative to the 5' splice site of the retained intron to -16 relative to the 3' splice site of the retained intron. In some cases, the targeted portion of the RIC pre-mRNA is in the retained intron within the region +498 relative to the 5' splice site of the retained intron to -496 relative to the 3' splice site of the retained intron. In some cases, the targeted portion of the RIC pre-mRNA is in the retained intron within the region +498 relative to the 5' splice site of the retained intron to -496 relative to the 3' splice site of the retained intron.

In some cases of any of the aforementioned methods, the target protein is PRPF3. In some cases, the targeted portion of the RIC pre-mRNA comprises a sequence that is at least about 80%, 85%, 90%, 95%, 97%, or 100% complimentary to any one of SEQ ID NOs 5-323. In some cases, the in the targeted portion of the RIC pre-mRNA comprises a sequence with at least 80%, 85%, 90%, 95%, 97%, or 100% sequence identity to a region comprising at least 8 contiguous nucleic acids of SEQ ID NO 447 or SEQ ID NO 446. In some cases, the ASO comprises a sequence with at least about 80%, 85%, 90%, 95%, 97%, or 100% sequence identity to any one of SEQ ID NOs 5-323. In some cases, the RIC pre-mRNA comprises a sequence with at least about 80%, 85%, 90%, 95%, 97%, or 100% sequence identity to SEQ ID NO 3. In some cases, the RIC pre-mRNA is encoded by a genetic sequence with at least about 80%, 85%, 90%, 95%, 97%, or 100% sequence identity to SEQ ID NO 1.

In some cases, the target protein is PRPF8. In some cases, the targeted portion of the RIC pre-mRNA is in the retained intron within the region +156 relative to the 5' splice site of the retained intron to -156 relative to the 3' splice site of the retained intron. In some cases, the targeted portion of the RIC pre-mRNA comprises a sequence that is at least about 80%, 85%, 90%, 95%, 97%, or 100% complimentary to any one of SEQ ID NOs 324-445. In some cases, the targeted portion of the RIC pre-mRNA comprises a sequence with at least 80%, 85%, 90%, 95%, 97%, or 100% sequence identity to a region comprising at least 8 contiguous nucleic acids of SEQ ID NO 448. In some cases, the ASO comprises a sequence with at least about 80%, 85%, 90%, 95%, 97%, or 100% sequence identity to any one of SEQ ID NOs 234-445. In some cases, the RIC pre-mRNA comprises a sequence with at least about 80%, 85%, 90%, 95%, 97%, or 100% sequence identity to SEQ ID NO 4. In some cases, the RIC pre-mRNA is encoded by a genetic sequence with at least about 80%, 85%, 90%, 95%, 97%, or 100% sequence identity to SEQ ID NO 2.

In some cases of any of the aforementioned methods, the targeted portion of the RIC pre-mRNA is in the retained intron within: (a) the region +6 to +100 relative to the 5' splice site of the retained intron; or (b) the region -16 to -100 relative to the 3' splice site of the retained intron. In some cases, the antisense oligomer targets a portion of the RIC pre-mRNA that is within the region about 100 nucleotides downstream of the 5' splice site of the at least one retained intron, to about 100 nucleotides upstream of the 3' splice site of the at least one retained intron. In some cases, the targeted portion of the RIC pre-mRNA is the retained intron within the: (a) the region +2e to -4e in the exon flanking the 5' splice site of the retained intron; or (b) the region +2e to - 4e in the exon flanking the 3' splice site of the retained intron.

In some cases of any of the aforementioned methods, the antisense oligomer does not increase the amount of the target protein or the functional RNA by modulating alternative splicing of pre-mRNA transcribed from a gene encoding the functional RNA or target protein. In some cases, the antisense oligomer does not increase the amount of the target protein or the functional RNA by modulating aberrant splicing resulting from mutation of the gene encoding the target protein or the functional RNA. In some cases, the RIC pre-mRNA was produced by partial splicing of a full-length pre-mRNA or partial splicing of a wild-type pre-mRNA. In some cases, the mRNA encoding the target protein or functional RNA is a full-length mature mRNA, or a wild-type mature mRNA. In some cases, the target protein produced is full-length protein, or wild-type protein. In some cases, the total amount of the mRNA encoding the target protein or functional RNA produced in the cell contacted with the antisense oligomer is increased about 1.1 to about 10-fold, about 1.5 to about 10-fold, about 2 to about 10-fold, about 3 to about 10-fold, about 4 to about 10-fold, about 1.1 to about 5-fold, about 1.1 to about 6-fold, about 1.1 to about 7-fold, about 1.1 to about 8-fold, about 1.1 to about 9-fold, about 2 to about 5-fold, about 2 to about 6-fold, about 2 to about 7-fold, about 2 to about 8-fold, about 2 to about 9-fold, about 3 to about 6-fold, about 3 to about 7-fold, about 3 to about 8-fold, about 3 to about 9-fold, about 4 to about 7-fold, about 4 to about 8-fold, about 4 to about 9-fold, at least about 1.1-fold, at least about 1.5-fold, at least about 2-fold, at least about 2.5-fold, at least about 3-fold, at least about 3.5-fold, at least about 4-fold, at least about 5-fold, or at least about 10-fold, compared to the total amount of the mRNA encoding the target protein or functional RNA produced in a control cell. In some cases, the total amount of target protein produced by the cell contacted with the antisense oligomer is increased about 1.1 to about 10-fold, about 1.5 to about 10-fold, about 2 to about 10-fold, about 3 to about 10-fold, about 4 to about 10-fold, about 1.1 to about 5-fold, about 1.1 to about 6-fold, about 1.1 to about 7-fold, about 1.1 to about 8-fold, about 1.1 to about 9-fold, about 2 to about 5-fold, about 2 to about 6-fold, about 2 to about 7-fold, about 2 to about 8-fold, about 2 to about 9-fold, about 3 to about 6-fold, about 3 to about 7-fold, about 3 to about 8-fold, about 3 to about 9-fold, about 4 to about 7-fold, about 4 to about 8-fold, about 4 to about 9-fold, at least about 1.1-fold, at least about 1.5-fold, at least about 2-fold, at least about 2.5-fold, at least about 3-fold, at least about 3.5-fold, at least about 4-fold, at least about 5-fold, or at least about 10-fold, compared to the total amount of target protein produced by a control cell.

In some cases of any of the aforementioned methods, the antisense oligomer comprises a backbone modification comprising a phosphorothioate linkage or a phosphorodiamidate linkage. In some cases, the antisense oligomer comprises a phosphorodiamidate morpholino, a locked nucleic acid, a peptide nucleic acid, a 2'-O-methyl, a 2'-Fluoro, or a 2'-O-methoxyethyl moiety. In some cases, the antisense oligomer comprises at least one modified sugar moiety. In some cases, each sugar moiety is a modified sugar moiety. In some cases, the antisense oligomer consists of from 8 to 50 nucleobases, 8 to 40 nucleobases, 8 to 35 nucleobases, 8 to 30 nucleobases, 8 to 25 nucleobases, 8 to 20 nucleobases, 8 to 15 nucleobases, 9 to 50 nucleobases, 9 to 40 nucleobases, 9 to 35 nucleobases, 9 to 30 nucleobases, 9 to 25 nucleobases, 9 to 20 nucleobases, 9 to 15 nucleobases, 10 to 50 nucleobases, 10 to 40 nucleobases, 10 to 35 nucleobases, 10 to 30 nucleobases, 10 to 25 nucleobases, 10 to 20 nucleobases, 10 to 15 nucleobases, 11 to 50 nucleobases, 11 to 40 nucleobases, 11 to 35 nucleobases, 11 to 30 nucleobases, 11 to 25 nucleobases, 11 to 20 nucleobases, 11 to 15 nucleobases, 12 to 50 nucleobases, 12 to 40 nucleobases, 12 to 35 nucleobases, 12 to 30 nucleobases, 12 to 25 nucleobases, 12 to 20 nucleobases, or 12 to 15 nucleobases. In some cases, the antisense oligomer is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100%, complementary to the targeted portion of the RIC pre-mRNA encoding the protein.

In some cases of any of the aforementioned methods, the cell comprises a population of RIC pre-mRNAs transcribed from the gene encoding the target protein or functional RNA, wherein the population of RIC pre-mRNAs comprises two or more retained introns, and wherein the antisense oligomer binds to the most abundant retained intron in the population of RIC pre-mRNAs. In some cases, the binding of the antisense oligomer to the most abundant retained intron induces splicing out of the two or more retained introns from the population of RIC pre-mRNAs to produce mRNA encoding the target protein or functional RNA. In some cases, the cell comprises a population of RIC pre-mRNAs transcribed from the gene encoding the target protein or functional RNA, wherein the population of RIC pre-mRNAs comprises two or more retained introns, and wherein the antisense oligomer binds to the second most abundant retained intron in the population of RIC pre-mRNAs. In some cases, the binding of the antisense oligomer to the second most abundant retained intron induces splicing out of the two or more retained introns from the population of RIC pre-mRNAs to produce mRNA encoding the target protein or functional RNA. In some cases, the condition is a disease or disorder. In some cases, the disease or disorder is RP18 or RP13. In some cases, the target protein and the RIC pre-mRNA are encoded by the PRPF3 gene or PRPF8 gene. In some cases, the method further comprises assessing protein expression. In some cases, the subject is a human. In some cases, the subject is a non-human animal. In some cases, the subject is a fetus, an embryo, or a child. In some cases, the cells are ex vivo. In some cases, the antisense oligomer is administered by intravitreal injection, subretinal injection, topical application, implantation, intraperitoneal injection, intramuscular injection, subcutaneous injection, or intravenous injection of the subject. In some cases, the 9 nucleotides at -3e to -1e of the exon flanking the 5' splice site and +1 to +6 of the retained intron, are identical to the corresponding wild-type sequence. In some cases, the 16 nucleotides at -15 to -1 of the retained intron and +1e of the exon flanking the 3' splice site are identical to the corresponding wild-type sequence.

Disclosed herein, in some cases, are antisense oligomers as used in the methods described herein. In some cases, the antisense oligomer comprises a sequence with at least about 80%, 85%, 90%, 95%, 97%, or 100% sequence identity to any one of SEQ ID NOs 5-445.

Also disclosed herein, in some cases, are pharmaceutical compositions comprising any of the aforementioned antisense oligomers and an excipient.

Disclosed herein, in some cases, are methods of treating a subject in need thereof, by administering any of the aforementioned pharmaceutical compositions by intravitreal injection, subretinal injection, topical application, implantation, intraperitoneal injection, intramuscular injection, subcutaneous injection, or intravenous injection.

Disclosed herein, in some cases, are compositions comprising an antisense oligomer for use in a method of increasing expression of a target protein or a functional RNA by cells to treat RP18 or RP13 in a subject in need thereof, associated with a deficient protein or deficient functional RNA, wherein the deficient protein or deficient functional RNA is deficient in amount or activity in the subject, wherein the antisense oligomer enhances constitutive splicing of a retained intron-containing pre-mRNA (RIC pre-mRNA) encoding the target protein or the functional RNA, wherein the target protein is: the deficient protein; or a compensating protein which functionally augments or replaces the deficient protein or in the subject; and wherein the function RNA is: the deficient RNA; or a compensating functional RNA which functionally augments or replaces the deficient functional RNA in the subject; wherein the RIC pre-mRNA comprises a retained intron, an exon flanking the 5' splice site and an exon flanking the 3' splice site, and wherein the retained intron is spliced from the RIC pre-mRNA encoding the target protein or the functional RNA, thereby increasing production or activity of the target protein or the functional RNA in the subject.

Disclosed herein, in some cases, are compositions comprising an antisense oligomer for use in a method of treating a condition associated with PRPF3 or PRPF8 protein in a subject in need thereof, the method comprising the step of increasing expression of PRPF3 or PRPF8 protein by cells of the subject, wherein the cells have a retained-intron-containing pre-mRNA (RIC pre-mRNA) comprising a retained intron, an exon flanking the 5' splice site of the retained intron, an exon flanking the 3' splice site of the retained intron, and wherein the RIC pre-mRNA encodes the PRPF3 or PRPF8 protein, the method comprising contacting the cells with the antisense oligomer, whereby the retained intron is constitutively spliced from the RIC pre-mRNA transcripts encoding PRPF3 or PRPF8 protein, thereby increasing the level of mRNA encoding PRPF3 or PRPF8 protein, and increasing the expression of PRPF3 or PRPF8 protein, in the cells of the subject. In some cases, the target protein PRPF3 is encoded by the sequence at NM_004698 or PRPF8 or encoded by the sequence at NM_006445. In some cases, the condition is a disease or disorder. In some cases, the disease or disorder is RP18 or RP13. In some cases, the target protein and RIC pre-mRNA are encoded by the PRPF3 or PRPF8 gene. In some cases, the antisense oligomer targets a portion of the RIC pre-mRNA that is in the retained intron within the region +6 relative to the 5' splice site of the retained intron to -16 relative to the 3' splice site of the retained intron. In some cases, the targeted portion of the RIC pre-mRNA is in the retained intron within the region +498 relative to the 5' splice site of the retained intron to -496 relative to the 3' splice site of the retained intron. In some cases, the target protein in PRPF3. In some cases, the targeted portion of the RIC pre-mRNA is in the retained intron within the region +498 relative to the 5' splice site of the retained intron to -496 relative to the 3' splice site of the retained intron. In some cases, the targeted portion of the RIC pre-mRNA comprises a sequence that is at least about 80%, 85%, 90%, 95%, 97%, or 100% complimentary to any one of SEQ ID NOs 5-323. In some cases, the targeted portion of the RIC pre-mRNA comprises a sequence with at least 80%, 85%, 90%, 95%, 97%, or 100% sequence identity to a region comprising at least 8 contiguous nucleic acids of SEQ ID NO 447 or SEQ ID NO 446. In some cases, the ASO comprises a sequence with at least about 80%, 85%, 90%, 95%, 97%, or 100% sequence identity to any one of SEQ ID NOs 5-323. In some cases, the RIC pre-mRNA comprises a sequence with at least about 80%, 85%, 90%, 95%, 97%, or 100% sequence identity to SEQ ID NO 3. In some cases, the RIC pre-mRNA is encoded by a genetic sequence with at least about 80%, 85%, 90%, 95%, 97%, or 100% sequence identity to SEQ ID NO 1. In some cases, the target protein is PRPF8. In some cases, the targeted portion of the RIC pre-mRNA is in the retained intron within the region +156 relative to the 5' splice site of the retained intron to -156 relative to the 3' splice site of the retained intron. In some cases, the targeted portion of the RIC pre-mRNA comprises a sequence that is at least about 80%, 85%, 90%, 95%, 97%, or 100% complimentary to any one of SEQ ID NOs 324-445. In some cases, the targeted portion of the RIC pre-mRNA comprises a sequence with at least 80%, 85%, 90%, 95%, 97%, or 100% sequence identity to a region comprising at least 8 contiguous nucleic acids of SEQ ID NO 448. In some cases, the ASO comprises a sequence with at least about 80%, 85%, 90%, 95%, 97%, or 100% sequence identity to any one of SEQ ID NOs 234-445. In some cases, the RIC pre-mRNA comprises a sequence with at least about 80%, 85%, 90%, 95%, 97%, or 100% sequence identity to SEQ ID NO 4. In some cases, the RIC pre-mRNA is encoded by a genetic sequence with at least about 80%, 85%, 90%, 95%, 97%, or 100% sequence identity to SEQ ID NO 2. In some cases, the antisense oligomer targets a portion of the RIC pre-mRNA that is in the retained intron within: (a) the region +6 to +100 relative to the 5' splice site of the retained intron; or (b) the region -16 to -100 relative to the 3' splice site of the retained intron. In some cases, the antisense oligomer targets a portion of the RIC pre-mRNA that is within the region about 100 nucleotides downstream of the 5' splice site of the at least one retained intron, to about 100 nucleotides upstream of the 3' splice site of the at least one retained intron. In some cases, the targeted portion of the RIC pre-mRNA is within: (a) the region +2e to -4e in the exon flanking the 5' splice site of the retained intron; or (b) the region +2e to -4e in the exon flanking the 3' splice site of the retained intron.

In some cases of any of the aforementioned compositions, the antisense oligomer does not increase the amount of target protein or functional RNA by modulating alternative splicing of the pre-mRNA transcribed from a gene encoding the target protein or functional RNA. In some cases, the antisense oligomer does not increase the amount of the functional RNA or functional protein by modulating aberrant splicing resulting from mutation of the gene encoding the target protein or functional RNA. In some cases, the RIC pre-mRNA was produced by partial splicing from a full-length pre-mRNA or a wild-type pre-mRNA. In some cases, the mRNA encoding the target protein or functional RNA is a full-length mature mRNA, or a wild-type mature mRNA. In some cases, the target protein produced is full-length protein, or wild-type protein. In some cases, the retained intron is a rate-limiting intron. In some cases, the retained intron is the most abundant retained intron in the RIC pre-mRNA. In some cases, the retained intron is the second most abundant retained intron in the RIC pre-mRNA.

In some cases of any of the aforementioned compositions, the antisense oligomer comprises a backbone modification comprising a phosphorothioate linkage or a phosphorodiamidate linkage. In some cases, the antisense oligomer is an antisense oligonucleotide. In some cases, the antisense oligomer comprises a phosphorodiamidate morpholino, a locked nucleic acid, a peptide nucleic acid, a 2'-O-methyl, a 2'-Fluoro, or a 2'-O-methoxyethyl moiety. In some cases, the antisense oligomer comprises at least one modified sugar moiety. In some cases, each sugar moiety is a modified sugar moiety. In some cases, the antisense oligomer consists of from 8 to 50 nucleobases, 8 to 40 nucleobases, 8 to 35 nucleobases, 8 to 30 nucleobases, 8 to 25 nucleobases, 8 to 20 nucleobases, 8 to 15 nucleobases, 9 to 50 nucleobases, 9 to 40 nucleobases, 9 to 35 nucleobases, 9 to 30 nucleobases, 9 to 25 nucleobases, 9 to 20 nucleobases, 9 to 15 nucleobases, 10 to 50 nucleobases, 10 to 40 nucleobases, 10 to 35 nucleobases, 10 to 30 nucleobases, 10 to 25 nucleobases, 10 to 20 nucleobases, 10 to 15 nucleobases, 11 to 50 nucleobases, 11 to 40 nucleobases, 11 to 35 nucleobases, 11 to 30 nucleobases, 11 to 25 nucleobases, 11 to 20 nucleobases, 11 to 15 nucleobases, 12 to 50 nucleobases, 12 to 40 nucleobases, 12 to 35 nucleobases, 12 to 30 nucleobases, 12 to 25 nucleobases, 12 to 20 nucleobases, or 12 to 15 nucleobases. In some cases, n the antisense oligomer is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or is 100% complementary to the targeted portion of the RIC pre-mRNA encoding the protein.

Disclosed herein, in some cases, are pharmaceutical compositions comprising the antisense oligomer of any of the aforementioned compositions and an excipient.

Disclosed herein, in some cases, are methods of treating a subject in need thereof, by administering any of the aforementioned pharmaceutical compositions by intravitreal injection, subretinal injection, topical application, implantation, intraperitoneal injection, intramuscular injection, subcutaneous injection, or intravenous injection of the subject.

Disclosed herein, in some cases, are pharmaceutical compositions comprising: an antisense oligomer that hybridizes to a target sequence of a deficient PRPF3 mRNA transcript, wherein the deficient PRPF3 mRNA transcript comprises a retained intron, wherein the antisense oligomer induces splicing out of the retained intron from the deficient PRPF3 mRNA transcript; and a pharmaceutical acceptable excipient. In some cases, the deficient PRPF3 mRNA transcript is a PRPF3 RIC pre-mRNA transcript. In some cases, the targeted portion of the PRPF3 RIC pre-mRNA transcript is in the retained intron within the region +500 relative to the 5' splice site of the retained intron to -500 relative to the 3' spliced site of the retained intron. In some cases, the PRPF3 RIC pre-mRNA transcript is encoded by a genetic sequence with at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 1. In some cases, the PRPF3 RIC pre-mRNA transcript comprises a sequence with at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to any one of SEQ ID NOs: 3-4. In some cases, the antisense oligomer comprises a backbone modification comprising a phosphorothioate linkage or a phosphorodiamidate linkage. In some cases, the antisense oligomer is an antisense oligonucleotide. In some cases, the antisense oligomer comprises a phosphorodiamidate morpholino, a locked nucleic acid, a peptide nucleic acid, a 2'-O-methyl, a 2'-Fluoro, or a 2'-O-methoxyethyl moiety. In some cases, the antisense oligomer comprises at least one modified sugar moiety. In some cases, the antisense oligomer comprises from 8 to 50 nucleobases, 8 to 40 nucleobases, 8 to 35 nucleobases, 8 to 30 nucleobases, 8 to 25 nucleobases, 8 to 20 nucleobases, 8 to 15 nucleobases, 9 to 50 nucleobases, 9 to 40 nucleobases, 9 to 35 nucleobases, 9 to 30 nucleobases, 9 to 25 nucleobases, 9 to 20 nucleobases, 9 to 15 nucleobases, 10 to 50 nucleobases, 10 to 40 nucleobases, 10 to 35 nucleobases, 10 to 30 nucleobases, 10 to 25 nucleobases, 10 to 20 nucleobases, 10 to 15 nucleobases, 11 to 50 nucleobases, 11 to 40 nucleobases, 11 to 35 nucleobases, 11 to 30 nucleobases, 11 to 25 nucleobases, 11 to 20 nucleobases, 11 to 15 nucleobases, 12 to 50 nucleobases, 12 to 40 nucleobases, 12 to 35 nucleobases, 12 to 30 nucleobases, 12 to 25 nucleobases, 12 to 20 nucleobases, or 12 to 15 nucleobases. In some cases, the antisense oligomer is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or is 100% complementary to a targeted portion of the PRPF3 RIC pre-mRNA transcript. In some cases, the targeted portion of the PRPF3 RIC pre-mRNA transcript is within a sequence selected from SEQ ID NOs: 446-447. In some cases, the antisense oligomer comprises a nucleotide sequence that is at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 5-323. In some cases, the antisense oligomer comprises a nucleotide sequence selected from SEQ ID NOs: 5-323. In some cases, the pharmaceutical composition is formulated for intrathecal injection, intracerebroventricular injection, intraperitoneal injection, intramuscular injection, subcutaneous injection, or intravenous injection.

Disclosed herein, in some cases, are pharmaceutical compositions comprising: an antisense oligomer that hybridizes to a target sequence of a deficient PRPF8 mRNA transcript, wherein the deficient PRPF8 mRNA transcript comprises a retained intron, wherein the antisense oligomer induces splicing out of the retained intron from the deficient PRPF8 mRNA transcript; and a pharmaceutical acceptable excipient. In some cases, the deficient PRPF8 mRNA transcript is a PRPF8 RIC pre-mRNA transcript. In some cases, the targeted portion of the PRPF8 RIC pre-mRNA transcript is in the retained intron within the region +500 relative to the 5' splice site of the retained intron to -500 relative to the 3' spliced site of the retained intron. In some cases, the PRPF8 RIC pre-mRNA transcript is encoded by a genetic sequence with at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 2. In some cases, the PRPF8 RIC pre-mRNA transcript comprises a sequence with at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to any one of SEQ ID NOs: 3-4. In some cases, the antisense oligomer comprises a backbone modification comprising a phosphorothioate linkage or a phosphorodiamidate linkage. In some cases, the antisense oligomer is an antisense oligonucleotide. In some cases, the antisense oligomer comprises a phosphorodiamidate morpholino, a locked nucleic acid, a peptide nucleic acid, a 2'-O-methyl, a 2'-Fluoro, or a 2'-O-methoxyethyl moiety. In some cases, the antisense oligomer comprises at least one modified sugar moiety. In some cases, the antisense oligomer comprises from 8 to 50 nucleobases, 8 to 40 nucleobases, 8 to 35 nucleobases, 8 to 30 nucleobases, 8 to 25 nucleobases, 8 to 20 nucleobases, 8 to 15 nucleobases, 9 to 50 nucleobases, 9 to 40 nucleobases, 9 to 35 nucleobases, 9 to 30 nucleobases, 9 to 25 nucleobases, 9 to 20 nucleobases, 9 to 15 nucleobases, 10 to 50 nucleobases, 10 to 40 nucleobases, 10 to 35 nucleobases, 10 to 30 nucleobases, 10 to 25 nucleobases, 10 to 20 nucleobases, 10 to 15 nucleobases, 11 to 50 nucleobases, 11 to 40 nucleobases, 11 to 35 nucleobases, 11 to 30 nucleobases, 11 to 25 nucleobases, 11 to 20 nucleobases, 11 to 15 nucleobases, 12 to 50 nucleobases, 12 to 40 nucleobases, 12 to 35 nucleobases, 12 to 30 nucleobases, 12 to 25 nucleobases, 12 to 20 nucleobases, or 12 to 15 nucleobases. In some cases, the antisense oligomer is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or is 100% complementary to a targeted portion of the PRPF8 RIC pre-mRNA transcript. In some cases, the targeted portion of the PRPF8 RIC pre-mRNA transcript is within a sequence selected from SEQ ID NOs: 448. In some cases, the antisense oligomer comprises a nucleotide sequence that is at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 324-445. In some cases, the antisense oligomer comprises a nucleotide sequence selected from SEQ ID NOs: 324-445. In some cases, the pharmaceutical composition is formulated for intravitreal injection, subretinal injection, topical application, implantation, intraperitoneal injection, intramuscular injection, subcutaneous injection, or intravenous injection.

Disclosed herein, in some cases, are methods of inducing processing of a deficient PRPF3 mRNA transcript to facilitate removal of a retained intron to produce a fully processed PRPF3 mRNA transcript that encodes a functional form of a PRPF3 protein, the method comprising: (a) contacting an antisense oligomer to a target cell of a subject; (b) hybridizing the antisense oligomer to the deficient PRPF3 mRNA transcript, wherein the deficient PRPF3 mRNA transcript is capable of encoding the functional form of a PRPF3 protein and comprises at least one retained intron; (c) removing the at least one retained intron from the deficient PRPF3 mRNA transcript to produce the fully processed PRPF3 mRNA transcript that encodes the functional form of PRPF3 protein; and (d) translating the functional form of PRPF3 protein from the fully processed PRPF3 mRNA transcript. In some cases, the retained intron is an entire retained intron. In some cases, the deficient PRPF3 mRNA transcript is a PRPF3 RIC pre-mRNA transcript.

Disclosed herein, in some cases, are methods of treating a subject having a condition caused by a deficient amount or activity of PRPF3 protein comprising administering to the subject an antisense oligomer comprising a nucleotide sequence with at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 5-323.

Disclosed herein, in some cases, are methods of inducing processing of a deficient PRPF8 mRNA transcript to facilitate removal of a retained intron to produce a fully processed PRPF8 mRNA transcript that encodes a functional form of a PRPF8 protein, the method comprising: (a) contacting an antisense oligomer to a target cell of a subject; (b) hybridizing the antisense oligomer to the deficient PRPF8 mRNA transcript, wherein the deficient PRPF8 mRNA transcript is capable of encoding the functional form of a PRPF8 protein and comprises at least one retained intron; (c) removing the at least one retained intron from the deficient PRPF8 mRNA transcript to produce the fully processed PRPF8 mRNA transcript that encodes the functional form of PRPF8 protein; and (d) translating the functional form of PRPF8 protein from the fully processed PRPF8 mRNA transcript. In some cases, the retained intron is an entire retained intron. In some cases, the deficient PRPF8 mRNA transcript is a PRPF8 RIC pre-mRNA transcript.

Disclosed herein, in some cases, are methods of treating a subject having a condition caused by a deficient amount or activity of PRPF8 protein comprising administering to the subject an antisense oligomer comprising a nucleotide sequence with at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 324-445.

BRIEF DESCRIPTION OF THE DRAWINGS

The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features of the present disclosure will be obtained by reference to the following illustrative drawings.

• FIG. 1 depicts a schematic representation of an exemplary retained-intron-containing (RIC) pre-mRNA transcript. The 5' splice site consensus sequence is indicated with underlined letters (letters are nucleotides; upper case: exonic portion and lower case: intronic portion) from - 3e to -1e and +1 to +6 (numbers labeled "e" are exonic and unlabeled numbers are intronic). The 3' splice site consensus sequence is indicated with underlined letters (letters are nucleotides; upper case: exonic portion and lower case: intronic portion) from -15 to -1 and +1e (numbers labeled "e" are exonic and unlabeled numbers are intronic). Intronic target regions for ASO screening comprise nucleotides +6 relative to the 5' splice site of the retained intron (arrow at left) to -16 relative to the 3' splice site of the retained intron (arrow at right). In cases, intronic target regions for ASO screening comprise nucleotides +6 to +100 relative to the 5' splice site of the retained intron and -16 to -100 relative to the 3' splice site of the retained intron. Exonic target regions comprise nucleotides +2e to -4e in the exon flanking the 5' splice site of the retained intron and +2e to -4e in the exon flanking the 3' splice site of the retained intron. "n" or "N" denote any nucleotide, "y" denotes pyrimidine. The sequences shown represent consensus sequences for mammalian splice sites and individual introns and exons need not match the consensus sequences at every position.
• FIG. 2A depicts an exemplary representation of the Targeted Augmentation of Nuclear Gene Output (TANGO) approach. FIG. 2A shows a cell divided into nuclear and cytoplasmic compartments. In the nucleus, a pre-mRNA transcript of a target gene consisting of exons (rectangles) and introns (connecting lines) undergoes splicing to generate an mRNA, and this mRNA is exported to the cytoplasm and translated into target protein. For this target gene, the splicing of intron 1 is inefficient and a retained intron-containing (RIC) pre-mRNA accumulates primarily in the nucleus, and if exported to the cytoplasm, is degraded, leading to no target protein production.
• FIG. 2B depicts an exemplary schematic representation of the Targeted Augmentation of Nuclear Gene Output (TANGO) approach. FIG. 2B shows an example of the same cell as in FIG. 2A divided into nuclear and cytoplasmic compartments. Treatment with an antisense oligomer (ASO) promotes the splicing of intron 1 and results in an increase in mRNA, which is in turn translated into higher levels of target protein
• FIG. 3 depicts intron-retention in the PRPF3 gene with intron 12 detail. The identification of intron-retention events in the PRPF3 gene using RNA sequencing (RNAseq) is shown, visualized in the UCSC genome browser. The upper panel shows the read density corresponding to the PRPF3 transcript expressed in ARPE-19 (retina epithelial) cells and localized in either the cytoplasmic (top) or nuclear fraction (bottom). At the bottom of this panel, a graphic representation of the PRPF3 gene is shown to scale. The read density is shown as peaks. The highest read density corresponds to exons (black boxes), while no reads are observed for the majority of the introns (lines with arrow heads) in either cellular fraction. Higher read density is detected for intron 12 (indicated by the arrow) in the nuclear fraction compared to the cytoplasmic fraction indicating that splicing efficiency of intron 12 is low, resulting in intron retention. The retained-intron containing pre-mRNA transcripts are retained in the nucleus and are not exported out to the cytoplasm. The read density for intron 12 in renal epithelial cells is shown in detail in the lower panel.
• FIG. 4 illustrates a graphic representation of the ASO walk performed for PRPF3 IVS 12 targeting sequences immediately downstream of the 5' splice site or upstream of the 3' splice site using 2'-O-Me ASOs, PS backbone, is shown. ASOs were designed to cover these regions by shifting 5 nucleotides at a time (with the exception of ASO P3-IVS12+28). The PRPF3 exon-intron structure is drawn to scale.
• FIG. 5 depicts intron-retention in the PRPF3 gene with intron 13. Intron retention in the PRPF3 gene was identified by RNA sequencing (RNAseq), visualized in the UCSC genome browser, as described herein in the Examples. The read density for intron 13 in ARPE-19 cells is shown in detail in the lower panel.
• FIG. 6 illustrates a graphic representation of the ASO walk performed for PRPF3 IVS 13 targeting sequences immediately downstream of the 5' splice site or upstream of the 3' splice site using 2'-O-Me ASOs, PS backbone, is shown. ASOs were designed to cover these regions by shifting 5 nucleotides at a time (with the exception of ASO P3-IVS13+15, P3-IVS13+31, and P3-IVS13-47). The PRPF3 exon-intron structure is drawn to scale.
• FIG. 7 depicts intron-retention in the PRPF8 gene with intron 31 detail. The identification of intron-retention events in the PRPF8 gene using RNA sequencing (RNAseq) is shown, visualized in the UCSC genome browser. The upper panel shows the read density corresponding to the PRPF8 transcript expressed in ARPE-19 (retina epithelial) cells and localized in either the cytoplasmic (top) or nuclear fraction (bottom). At the bottom of this panel, a graphic representation of the PRPF8 gene is shown to scale. The read density is shown as peaks. The highest read density corresponds to exons (black boxes), while no reads are observed for the majority of the introns (lines with arrow heads) in either cellular fraction. Higher read density is detected for intron 31 (indicated by the arrow) in the nuclear fraction compared to the cytoplasmic fraction indicating that splicing efficiency of intron 31 is low, resulting in intron retention. The retained-intron containing pre-mRNA transcripts are retained in the nucleus and are not exported out to the cytoplasm. The read density for intron 31 in renal epithelial cells is shown in detail in the lower panel.
• FIG. 8 illustrates a graphic representation of the ASO walk performed for PRPF8 IVS 31 targeting sequences immediately downstream of the 5' splice site or upstream of the 3' splice site using 2'-O-Me ASOs, PS backbone, is shown. ASOs were designed to cover these regions by shifting 5 nucleotides at a time. The PRPF8 exon-intron structure is drawn to scale.
• FIG. 9 depicts a schematic of the RefSeq Genes for PRPF3 corresponding to NM_004698. The Percent Intron Retention (PIR) of the circled intron is shown.
• FIG. 10 depicts an exemplary graph is depicted showing the average (n=3) fold change in expression levels of PRPF3 mRNA without intron 12 in ARPE-19 cells treated for 24 hrs with 80 nM of the indicated ASOs over mock treated cells. Data is normalized to RPL32 expression.
• FIG. 11 depicts a schematic of the RefSeq Genes for PRPF3 corresponding to NM_004698. The Percent Intron Retention (PIR) of the circled intron is shown.
• FIG. 12 depicts an exemplary graph showing the average (n=3) fold change in expression levels of PRPF3 mRNA without intron 13 in ARPE-19 cells treated for 24 hrs with 80 nM of the indicated ASOs over mock treated cells. Data is normalized to RPL32 expression.
• FIG. 13 depicts a schematic of the RefSeq Genes for PRPF8 corresponding to NM_006445. The Percent Intron Retention (PIR) of the circled intron is shown.
• FIG. 14 depicts an exemplary graph is depicted showing the average (n=3) fold change in expression levels of PRPF8 mRNA without intron 31 in ARPE-19 cells treated for 24 hrs with 80 nM of the indicated ASOs over mock treated cells. Data is normalized to RPL32 expression.

DETAILED DESCRIPTION

Individual introns in primary transcripts of protein-coding genes having more than one intron are spliced from the primary transcript with different efficiencies. In most cases only the fully spliced mRNA is exported through nuclear pores for subsequent translation in the cytoplasm. Unspliced and partially spliced transcripts are detectable in the nucleus. It is generally thought that nuclear accumulation of transcripts that are not fully spliced is a mechanism to prevent the accumulation of potentially deleterious mRNAs in the cytoplasm that may be translated to protein. For some genes, splicing of the least efficient intron is a rate-limiting post-transcriptional step in gene expression, prior to translation in the cytoplasm.

Substantial levels of partially-spliced transcripts of the PRPF3 and PRPF8 genes, which encode the PRPF3 protein, deficient in RP18, and the PRPF8 protein, deficient in RP13, respectively, have been discovered in the nucleus of human cells. These PRPF3 and PRPF8 pre-mRNA species comprise at least one retained intron. Described herein are compositions and methods for upregulating splicing of one or more retained PRPF3 or PRPF8 introns that are rate-limiting for the nuclear stages of gene expression to increase steady-state production of fully-spliced, mature mRNA, and thus, translated PRPF3 or PRPF8 protein levels, respectively. These compositions and methods utilize antisense oligomers (ASOs) that promote constitutive splicing at an intron splice site of a retained-intron-containing PRPF3 or PRPF8 pre-mRNA that accumulates in the nucleus. Thus, PRPF3 or PRPF8 protein is increased using the methods of the disclosure to treat a condition caused by PRPF3 or PRPF8 protein deficiency. In other cases, the methods of the disclosure are used to increase PRPF3 or PRPF8 production to treat a condition in a subject in need thereof. In cases, the subject has condition in which PRPF3 or PRPF8 is not necessarily deficient relative to wild-type, but where an increase in PRPF3 or PRPF8 mitigates the condition nonetheless. In some cases, the condition is a caused by a PRPF3 or PRPF8 haploinsufficiency.

Retinitis Pigmentosa

Retinitis pigmentosa (RP) describes a debilitating group of eye disorders , including RP18, caused by a deficiency in the PRPF3 protein, and RP13, caused by a deficiency in the PRPF8 protein. Subjects having RP experience loss of night vision in the early phase of the disorder. Over time, loss of vision begins to occur, which eventually leads to tunnel vision. This loss in vision can be attributed to a dysfunction in the rod photoreceptor system. As the disorder progresses, the afflicted patient may lose a significant portion of their cone photoreceptors before experiencing loss of visual acuity (Berger et al., 2010).

The overall prevalence of RP diseases is estimated to be about 1:3500. The mutation of over 40 genes has been correlated to incidence of RP disease through three patterns of inheritance: autosomal dominant, autosomal recessive, and X-linked. The genes that have been implicated in the progression of RP diseases can be grouped into five main categories: i) phototransduction, ii) retinal metabolism, iii) tissue development and maintenance, iv) cellular structure, and v) splicing. The genes that comprise the splicing category (PRPF3, PRPF8, PRP31 and PAP1) are responsible for the assembly of the spliceosome protein complex that is responsible for removing intronic sequences from pre-mRNA. Studies have suggested that the progression of at least some cases of RP is due to haploinsuffiency, meaning that the presence of a single dysfunctional allele results in diminished expression of the corresponding protein (Berger et al., 2010).

PRPF3

The PRPF3 gene, which spans 16 exons and is located at 1q21.1, encodes the pre-mRNA processing factor 3 (PRPF3) protein. The PRPF3 canonical mRNA sequence is set forth at NCBI Reference Sequence: NM_004698. PRPF3 is a 77 kD, 682 amino acid protein that is involved in spliceosome assembly. Dysfunction of PRPF3 has been implicated in the progression of RP 18. It has been speculated that a retina-specific splicing element may interact with PRPF3 and generate the rod photoreceptor-specific phenotype. Missense mutations P493S and T494M in PRPF3 have both been shown to display the RP18 phenotype, linking dysfunction of PRPF3 with the RP 18 phenotype (Berger et al., 2010). RP18 and the PRPF3 gene are described by, e.g., OMIM #601414 (Online Mendelian Inheritance in Man, Johns Hopkins University, 1966-2015).

PRPF8

The PRPF8 gene, which spans 42 exons and is located at 17p13.3, codes for the pre-mRNA processing factor 8 (PRPF8) protein. The PRPF8 canonical mRNA sequence is set forth at NCBI Reference Sequence: NM_006445. PRPF8 is a 220 kD, 2,334 amino acid protein that is involved in spliceosome assembly. Dysfunction of PRPF8 has been implicated in the progression of RP13. PRPF8 mutants H2309P, H2309R, R2310K, P2301T, F2304L, R2310G and F2314L were found to result in the clinical phenotype of RP13, linking dysfunction of PRPF8 with RP13 (Berger et al., 2010). RP13 and the RP8 gene are described by, e.g., OMIM #600059 (Online Mendelian Inheritance in Man, Johns Hopkins University, 1966-2015).

Retained Intron Containing Pre-mRNA (RIC Pre-mRNA)

The methods of the present disclosure exploit the presence of retained-intron-containing pre-mRNA (RIC pre-mRNA) transcribed from the PRPF3 or the PRPF8 gene in the cell nucleus. Splicing of the identified RIC pre-mRNA species to produce mature, fully-spliced, mRNA, is induced using ASOs that stimulate splicing out of the retained introns. The resulting mature mRNA can be exported to the cytoplasm and translated, thereby increasing the amount of PRPF3 protein or PRPF8 protein in the patient's cells and alleviating symptoms of RP18 or RP13, respectively. This method, described further below, is known as Targeted Augmentation of Nuclear Gene Output (TANGO).

PRPF3 Nuclear Transcripts

As described herein in the Examples, the PRPF3 gene was analyzed for intron-retention events and retention of introns, e.g., introns 12 and 13, was observed. RNA sequencing (RNAseq), visualized in the UCSC genome browser, showed PRPF3 transcripts expressed in ARPE-19 cells and localized in either the cytoplasmic or nuclear fraction. In both fractions, reads were not observed for the majority of the introns. However, higher read density was detected for introns 12 and 13 in the nuclear fraction compared to the cytoplasmic fraction indicating that splicing efficiency of introns 12 and 13 is low, resulting in intron retention. The retained-intron containing pre-mRNA transcripts accumulate primarily in the nucleus and are not translated into the PRPF3 protein. The read density for introns 12 and 13, indicated 26%, and 33% intron retention, respectively. The percent intron retention (PIR) value for intron 12 was obtained by averaging four values (37, 35, 16, and 15). The PIR value for intron 13 was obtained similarly, by averaging the four values 34, 33, 34, and 31. Each value was determined in ARPE-19 (retinal pigmented epithelial) cells using one of four different algorithms.

In some cases, the PRPF3 intron number corresponds to the mRNA sequence at NM_004698. In some cases, the targeted portion of the PRPF3 RIC pre-mRNA is in intron 12 and/or 13. In cases, hybridization of an ASO to the targeted portion of a PRPF3 RIC pre-mRNA results in enhanced splicing at the splice site (5' splice site or 3' splice site) of at least one of retained PRPF3 introns 12 or 13 and subsequently increases PRPF3 protein production. It is understood that the intron numbering may change in reference to a different PRPF3 isoform sequence. One of skill in the art can determine the corresponding intron number in any PRPF3 isoform based on an intron sequence provided herein or using the intron number provided in reference to the mRNA sequence at NM_004698. One of skill in the art also can determine the sequences of flanking exons in any PRPF3 isoform for targeting using the methods of the disclosure, based on an intron sequence provided herein or using the intron number provided in reference to the mRNA sequence at NM_004698. In some cases, the compositions and methods of the present disclosure are used to increase the expression of any known PRPF3 isoform, e.g., as described in the NCBI Gene ID database at Gene ID 9129 (NCBI repository of biological and scientific information, operated by National Center for Biotechnology Information, National Library of Medicine, 8600 Rockville Pike, Bethesda, MD USA 20894).

In some cases, the PRPF8 intron numbering corresponds to the mRNA sequence at NM_006445. In some cases, the targeted portion of the PRPF8 RIC pre-mRNA is in intron 31. Hybridization of an ASO to the targeted portion of the RIC pre-mRNA results in enhanced splicing at the splice site (5' splice site or 3' splice site) of at least one of retained PRPF8 intron 31 and subsequently increases PRPF8 protein production. It is understood that the intron numbering may change in reference to a different PRPF8 isoform sequence. One of skill in the art can determine the corresponding intron number in any PRPF8 isoform based on an intron sequence provided herein or using the intron number provided in reference to the mRNA sequence at NM_006445. One of skill in the art also can determine the sequences of flanking exons in any PRPF8 isoform for targeting using the methods of the disclosure, based on an intron sequence provided herein or using the intron number provided in reference to the mRNA sequence at NM_006445. The compositions and methods of the present invention are used to increase the expression of any known PRPF8 isoform, e.g., as described in the NCBI Gene ID database at Gene ID 10594 (NCBI repository of biological and scientific information).

PRPF3

In some cases, the ASOs disclosed herein target a RIC pre-mRNA transcribed from a PRPF3 genomic sequence (a PRPF3 RIC pre-mRNA). In some cases, the PRPF3 genomic sequence is SEQ ID NO: 1. In some cases, the PRPF3 RIC pre-mRNA is SEQ ID NO: 3.

PRPF3: retained intron 12

In some cases, the PRPF3 RIC pre-mRNA transcript comprises retained intron 12. In some cases, when the PRPF3 RIC pre-mRNA transcript comprises retained intron 12, the ASOs disclosed herein target SEQ ID NO: 447. In some cases, when the PRPF3 RIC pre-mRNA transcript comprises retained intron 12, the ASO has a sequence according to any one of SEQ ID NOs: 5-239. In some cases, the ASOs target a PRPF3 RIC pre-mRNA sequence.

In some cases, the ASO targets exon 12 of PRPF3 RIC pre-mRNA comprising a retained intron 12. In some cases, the ASO targets an exon 12 sequence upstream (or 5') from the 5' splice site of a PRPF3 RIC pre-mRNA comprising a retained intron 12. In some cases, the ASO targets an exon sequence about 4 to about 94 nucleotides upstream (or 5') from the 5' splice site of a PRPF3 RIC pre-mRNA comprising a retained intron 12. In some cases, the ASO has a sequence according to any one of SEQ ID NOs: 5-23.

In some cases, the ASO targets intron 12 in a PRPF3 RIC pre-mRNA comprising a retained intron 12. In some cases, the ASO targets an intron 12 sequence downstream (or 3') from the 5' splice site of a PRPF3 RIC pre-mRNA comprising a retained intron 12. In some cases, the ASO targets an intron 12 sequence about 6 to about 498 nucleotides downstream (or 3') from the 5' splice site of a PRPF3 RIC pre-mRNA comprising a retained intron 12. In some cases, the ASO has a sequence according to any one of SEQ ID NOs: 24-121.

In some cases, the ASO targets an intron 12 sequence upstream (or 5') from the 3' splice site of a PRPF3 RIC pre-mRNA comprising a retained intron 12. In some cases, the ASO targets an intron 12 sequence about 16 to about 496 nucleotides upstream (or 5') from the 3' splice site of a PRPF3 RIC pre-mRNA a comprising retained intron 12. In some cases, the ASO has a sequence according to any one of SEQ ID NOs: 122-218.

In some cases, the ASO targets exon 13 in a PRPF3 RIC pre-mRNA comprising a retained intron 12. In some cases, the ASO targets an exon 13 sequence downstream (or 3') from the 3' splice site of a PRPF3 RIC pre-mRNA comprising a retained intron 12. In some cases, the ASO targets an exon 13 sequence about 2 to about 102 nucleotides downstream (or 3') from the 3' splice site of a PRPF3 RIC pre-mRNA comprising a retained intron 12. In some cases, the ASO has a sequence according to any one of SEQ ID NOs: 219-239.

PRPF3: retained intron 13

In some cases, the PRPF3 RIC pre-mRNA transcript comprises retained intron 13. In some cases, when the PRPF3 RIC pre-mRNA transcript comprises retained intron 13, the ASOs disclosed herein target SEQ ID NO: 446. In some cases, when the PRPF3 RIC pre-mRNA transcript comprises retained intron 13, the ASO has a sequence according to any one of SEQ ID NOs: 240-323. In some cases, the ASOs target a PRPF3 RIC pre-mRNA sequence.

In some cases, the ASO targets exon 13 of PRPF3 RIC pre-mRNA comprising a retained intron 13. In some cases, the ASO targets an exon 13 sequence upstream (or 5') from the 5' splice site of a PRPF3 RIC pre-mRNA comprising a retained intron 13. In some cases, the ASO targets an exon sequence about 4 to about 99 nucleotides upstream (or 5') from the 5' splice site of a PRPF3 RIC pre-mRNA comprising a retained intron 13. In some cases, the ASO has a sequence according to any one of SEQ ID NOs: 240-259.

In some cases, the ASO targets intron 13 in a PRPF3 RIC pre-mRNA comprising a retained intron 13. In some cases, the ASO targets an intron 13 sequence downstream (or 3') from the 5' splice site of a PRPF3 RIC pre-mRNA comprising a retained intron 13. In some cases, the ASO targets an intron 13 sequence about 6 to about 146 nucleotides downstream (or 3') from the 5' splice site of a PRPF3 RIC pre-mRNA comprising a retained intron 13. In some cases, the ASO has a sequence according to any one of SEQ ID NOs: 260-286.

In some cases, the ASO targets an intron 13 sequence upstream (or 5') from the 3' splice site of a PRPF3 RIC pre-mRNA comprising a retained intron 13. In some cases, the ASO targets an intron 13 sequence about 16 to about 146 nucleotides upstream (or 5') from the 3' splice site of a PRPF3 RIC pre-mRNA a comprising retained intron 13. In some cases, the ASO has a sequence according to any one of SEQ ID NOs: 287-310.

In some cases, the ASO targets exon 14 in a PRPF3 RIC pre-mRNA comprising a retained intron 13. In some cases, the ASO targets an exon 14 sequence downstream (or 3') from the 3' splice site of a PRPF3 RIC pre-mRNA comprising a retained intron 13. In some cases, the ASO targets an exon 14 sequence about 2 to about 67 nucleotides downstream (or 3') from the 3' splice site of a PRPF3 RIC pre-mRNA comprising a retained intron 13. In some cases, the ASO has a sequence according to any one of SEQ ID NOs: 311-323.

PRPF8

In some cases, the ASOs disclosed herein target a RIC pre-mRNA transcribed from a PRPF8 genomic sequence (a PRPF8 RIC pre-mRNA). In some cases, the PRPF8 genomic sequence is SEQ ID NO. 2. In some cases, the PRPF8 RIC pre-mRNA is SEQ ID NO. 4.

PRPF8: retained intron 31

In some cases, the PRPF8 RIC pre-mRNA transcript comprises retained intron 31. In some cases, when the PRPF8 RIC pre-mRNA transcript comprises retained intron 31, the ASOs disclosed herein target SEQ ID NO: 448. In some cases, when the PRPF8 RIC pre-mRNA transcript comprises retained intron 31, the ASO has a sequence according to any one of SEQ ID NOs: 324-445. In some cases, the ASOs target a PRPF8 RIC pre-mRNA sequence.

In some cases, the ASO targets exon 31 of PRPF8 RIC pre-mRNA comprising a retained intron 31. In some cases, the ASO targets an exon 31 sequence upstream (or 5') from the 5' splice site of a PRPF8 RIC pre-mRNA comprising a retained intron 31. In some cases, the ASO targets an exon sequence about 4 to about 144 nucleotides upstream (or 5') from the 5' splice site of a PRPF8 RIC pre-mRNA comprising a retained intron 31. In some cases, the ASO has a sequence according to any one of SEQ ID NOs: 324-350.

In some cases, the ASO targets intron 31 in a PRPF8 RIC pre-mRNA comprising a retained intron 31. In some cases, the ASO targets an intron 31 sequence downstream (or 3') from the 5' splice site of a PRPF8 RIC pre-mRNA comprising a retained intron 31. In some cases, the ASO targets an intron 31 sequence about 6 to about 156 nucleotides downstream (or 3') from the 5' splice site of a PRPF8 RIC pre-mRNA comprising a retained intron 31. In some cases, the ASO has a sequence according to any one of SEQ ID NOs: 351-381.

In some cases, the ASO targets an intron 31 sequence upstream (or 5') from the 3' splice site of a PRPF8 RIC pre-mRNA comprising a retained intron 31. In some cases, the ASO targets an intron 31 sequence about 16 to about 156 nucleotides upstream (or 5') from the 3' splice site of a PRPF8 RIC pre-mRNA a comprising retained intron 31. In some cases, the ASO has a sequence according to any one of SEQ ID NOs: 382-410.

In some cases, the ASO targets exon 32 in a PRPF8 RIC pre-mRNA comprising a retained intron 31. In some cases, the ASO targets an exon 32 sequence downstream (or 3') from the 3' splice site of a PRPF8 RIC pre-mRNA comprising a retained intron 31. In some cases, the ASO targets an exon 32 sequence about 2 to about 172 nucleotides downstream (or 3') from the 3' splice site of a PRPF8 RIC pre-mRNA comprising a retained intron 31. In some cases, the ASO has a sequence according to any one of SEQ ID NOs: 411-445.

Protein Expression

As described above, PRPF3 and PRPF8 mutations in RP diseases are spread across the entire protein. In some cases, the methods described herein are used to increase the production of a functional PRPF3 protein. In other cases, the methods described herein are used to increase the production of a functional PRPF8 protein. In other cases, the methods described herein are used to increase the production of a functional PRPF3 protein or PRPF8 protein. As used herein, the term "functional" refers to the amount of activity or function of a PRPF3 or PRPF8 protein that is necessary to eliminate any one or more symptoms of an RP disease. In some cases, the methods are used to increase the production of a partially functional PRPF3 protein. In other cases, the methods are used to increase the production of a partially functional PRPF8 protein. In other cases, the methods are used to increase the production of a partially functional PRPF3 or PRPF8 protein. As used herein, the term "partially functional" refers to any amount of activity or function of the PRPF3 or PRPF8 protein that is less than the amount of activity or function that is necessary to eliminate or prevent any one or more symptoms of a disease. In some cases, a partially functional protein or RNA will have at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, 85%, at least 90%, or at least 95% less activity relative to the fully functional protein or RNA.

In cases, the method is a method of increasing the expression of the PRPF3 protein by cells of a subject having a RIC pre-mRNA encoding the PRPF3 protein, wherein the subject has an RP disease caused by a deficient amount of activity of PRPF3 protein, and wherein the deficient amount of the PRPF3 protein is caused by haploinsufficiency of the PRPF3 protein. In such case, the subject has a first allele encoding a functional PRPF3 protein, and a second allele from which the PRPF3 protein is not produced. In another such case, the subject has a first allele encoding a functional PRPF3 protein, and a second allele encoding a nonfunctional PRPF3 protein. In another such case, the subject has a first allele encoding a functional PRPF3 protein, and a second allele encoding a partially functional PRPF3 protein. In any of these cases, the antisense oligomer binds to a targeted portion of the RIC pre-mRNA transcribed from the first allele (encoding functional PRPF3 protein), thereby inducing constitutive splicing of the retained intron from the RIC pre-mRNA, and causing an increase in the level of mature mRNA encoding functional PRPF3 protein, and an increase in the expression of the PRPF3 protein in the cells of the subject.

In some cases, the method is a method of increasing the expression of the PRPF8 protein by cells of a subject having a RIC pre-mRNA encoding the PRPF8 protein, wherein the subject has an RP disease caused by a deficient amount of activity of PRPF8 protein, and wherein the deficient amount of the PRPF8 protein is caused by haploinsufficiency of the PRPF8 protein. In such case, the subject has a first allele encoding a functional PRPF8 protein, and a second allele from which the PRPF8 protein is not produced. In another such case, the subject has a first allele encoding a functional PRPF8 protein, and a second allele encoding a nonfunctional PRPF8 protein. In another such case, the subject has a first allele encoding a functional PRPF8 protein, and a second allele encoding a partially functional PRPF8 protein. In any of these cases, the antisense oligomer binds to a targeted portion of the RIC pre-mRNA transcribed from the first allele (encoding functional PRPF8 protein), thereby inducing constitutive splicing of the retained intron from the RIC pre-mRNA, and causing an increase in the level of mature mRNA encoding functional PRPF8 protein, and an increase in the expression of the PRPF8 protein in the cells of the subject.

In some cases, the subject has a first allele encoding a functional PRPF3 protein, and a second allele encoding a partially functional PRPF3 protein, and the antisense oligomer binds to a targeted portion of the RIC pre-mRNA transcribed from the first allele (encoding functional PRPF3 protein) or a targeted portion of the RIC pre-mRNA transcribed from the second allele (encoding partially functional PRPF3 protein), thereby inducing constitutive splicing of the retained intron from the RIC pre-mRNA, and causing an increase in the level of mature mRNA encoding the PRPF3 protein, and an increase in the expression of functional or partially functional PRPF3 protein in the cells of the subject.

In other cases, the subject has a first allele encoding a functional PRPF8 protein, and a second allele encoding a partially functional PRPF8 protein, and the antisense oligomer binds to a targeted portion of the RIC pre-mRNA transcribed from the first allele (encoding functional PRPF8 protein) or a targeted portion of the RIC pre-mRNA transcribed from the second allele (encoding partially functional PRPF8 protein), thereby inducing constitutive splicing of the retained intron from the RIC pre-mRNA, and causing an increase in the level of mature mRNA encoding the PRPF8 protein, and an increase in the expression of functional or partially functional PRPF8 protein in the cells of the subject.

In related cases, the method is a method of using an ASO to increase the expression of a protein or functional RNA. In some cases, an ASO is used to increase the expression of PRPF3 protein in cells of a subject having a RIC pre-mRNA encoding PRPF3 protein, wherein the subject has a deficiency, e.g., RP18, in the amount or function of a PRPF3 protein.

In other related cases, the method is a method of using an ASO to increase the expression of a protein or functional RNA. In cases, an ASO is used to increase the expression of PRPF8 protein in cells of a subject having a RIC pre-mRNA encoding PRPF8 protein, wherein the subject has a deficiency, e.g., RP13, in the amount or function of a PRPF8 protein.

In cases, the RIC pre-mRNA transcript that encodes the protein that is causative of the disease is targeted by the ASOs described herein. In some cases, a RIC pre-mRNA transcript that encodes a protein that is not causative of the disease is targeted by the ASOs. For example, a disease that is the result of a mutation or deficiency of a first protein in a particular pathway may be ameliorated by targeting a RIC pre-mRNA that encodes a second protein, thereby increasing production of the second protein. In some cases, the function of the second protein is able to compensate for the mutation or deficiency of the first protein (which is causative of the disease or condition).

In cases, the subject has:

1. a. a first mutant allele from which
   1. i) the PRPF3 protein is produced at a reduced level compared to productionfrom a wild-type allele,
   2. ii) the PRPF3 protein is produced in a form having reduced function compared to an equivalent wild-type protein, or
   3. iii) the PRPF3 protein or functional RNA is not produced; and
2. b.a second mutant allele from which
   1. i) the PRPF3 protein is produced at a reduced level compared to production from a wild-type allele,
   2. ii) the PRPF3 protein is produced in a form having reduced function compared to an equivalent wild-type protein, or
   3. iii) the PRPF3 protein is not produced, and

wherein the RIC pre-mRNA is transcribed from the first allele and/or the second allele. In these cases, the ASO binds to a targeted portion of the RIC pre-mRNA transcribed from the first allele or the second allele, thereby inducing constitutive splicing of the retained intron from the RIC pre-mRNA, and causing an increase in the level of mRNA encoding PRPF3 protein and an increase in the expression of the target protein or functional RNA in the cells of the subject. In these cases, the target protein or functional RNA having an increase in expression level resulting from the constitutive splicing of the retained intron from the RIC pre-mRNA is either in a form having reduced function compared to the equivalent wild-type protein (partially-functional), or having full function compared to the equivalent wild-type protein (fully-functional).

In cases, the subject has:

1. a. a first mutant allele from which
   1. i) the PRPF8 protein is produced at a reduced level compared to production from a wild-type allele,
   2. ii) the PRPF8 protein is produced in a form having reduced function compared to an equivalent wild-type protein, or
   3. iii) the PRPF8 protein or functional RNA is not produced; and
2. b.a second mutant allele from which
   • iv) the PRPF8 protein is produced at a reduced level compared to production from a wild-type allele,
   • v) the PRPF8 protein is produced in a form having reduced function compared to an equivalent wild-type protein, or
   • vi) the PRPF8 protein is not produced, and

wherein the RIC pre-mRNA is transcribed from the first allele and/or the second allele. In these cases, the ASO binds to a targeted portion of the RIC pre-mRNA transcribed from the first allele or the second allele, thereby inducing constitutive splicing of the retained intron from the RIC pre-mRNA, and causing an increase in the level of mRNA encoding PRPF8 protein and an increase in the expression of the target protein or functional RNA in the cells of the subject. In these cases, the target protein or functional RNA having an increase in expression level resulting from the constitutive splicing of the retained intron from the RIC pre-mRNA is either in a form having reduced function compared to the equivalent wild-type protein (partially-functional), or having full function compared to the equivalent wild-type protein (fully-functional).

In cases, the level of mRNA encoding PRPF3 or PRPF8 protein is increased 1.1 to 10-fold, when compared to the amount of mRNA encoding PRPF3 or PRPF8 that is produced in a control cell, e.g., one that is not treated with the antisense oligomer or one that is treated with an antisense oligomer that does not bind to the targeted portion of the PRPF3 or PRPF8 RIC pre-mRNA.

In cases, the condition caused by a deficient amount or activity of PRPF3 or PRPF8 protein is not a condition caused by alternative or aberrant splicing of the retained intron to which the ASO is targeted. In cases, the condition caused by a deficient amount or activity of the PRPF3 or PRPF8 protein is not a condition caused by alternative or aberrant splicing of any retained intron in a RIC pre-mRNA encoding the PRPF3 or PRPF8 protein.

In some cases, a subject treated using the methods of the disclosure expresses a partially functional PRPF3 or PRPF8 protein from one allele, wherein the partially functional PRPF3 or PRPF8 protein is caused by a frameshift mutation, a nonsense mutation, a missense mutation, or a partial gene deletion. In cases, a subject treated using the methods of the disclosure expresses a nonfunctional PRPF3 or PRPF8 protein from one allele, wherein the nonfunctional PRPF3 or PRPF8 protein is caused by a frameshift mutation, a nonsense mutation, a missense mutation, a partial gene deletion, in one allele. In cases, a subject treated using the methods of the disclosure has a PRPF3 or PRPF8 whole gene deletion, in one allele.

In some cases, the subject has a PRPF3 missense mutation selected from P493S and T494M. In other cases, the subject has a PRPF8 missense mutation selected from H2309P, H2309R, R2310K, P2301T, F2304L, R2310G and F2314L. In cases, a subject having any mutation known in the art and described in the literature, e.g., by McKie et al 2001 referenced above, is treated using the methods and compositions of the present disclosure.

Use of TANGO for Increasing Protein Expression

As described above, in some cases, Targeted Augmentation of Nuclear Gene Output (TANGO) is used in the methods of the disclosure to increase expression of a PRPF3 or PRPF8 protein. In these cases, a retained-intron-containing pre-mRNA (RIC pre-mRNA) encoding PRPF3 or PRPF8 protein is present in the nucleus of a cell. Cells having a PRPF3 or PRPF8 RIC pre-mRNA that comprises a retained intron, an exon flanking the 5' splice site, and an exon flanking the 3' splice site, encoding the PRPF3 or PRPF8 protein, are contacted with antisense oligomers (ASOs) that are complementary to a targeted portion of the RIC pre-mRNA. Hybridization of the ASOs to the targeted portion of the RIC pre-mRNA results in enhanced splicing at the splice site (5' splice site or 3' splice site) of the retained intron and subsequently increases target protein production.

The terms "pre-mRNA," and "pre-mRNA transcript" may be used interchangeably and refer to any pre-mRNA species that contains at least one intron. In cases, pre-mRNA or pre-mRNA transcripts comprise a 5'-7-methylguanosine cap and/or a poly-A tail. In cases, pre-mRNA or pre-mRNA transcripts comprise both a 5'-7-methylguanosine cap and a poly-A tail. In some cases, the pre-mRNA transcript does not comprise a 5'-7-methylguanosine cap and/or a poly-A tail. A pre-mRNA transcript is a non-productive messenger RNA (mRNA) molecule if it is not translated into a protein (or transported into the cytoplasm from the nucleus).

As used herein, a "retained-intron-containing pre-mRNA" ("RIC pre-mRNA") is a pre-mRNA transcript that contains at least one retained intron. The RIC pre-mRNA contains a retained intron, an exon flanking the 5' splice site of the retained intron, an exon flanking the 3' splice site of the retained intron, and encodes the target protein. An "RIC pre-mRNA encoding a target protein" is understood to encode the target protein when fully spliced. A "retained intron" is any intron that is present in a pre-mRNA transcript when one or more other introns, such as an adjacent intron, encoded by the same gene have been spliced out of the same pre-mRNA transcript. In some cases, the retained intron is the most abundant intron in RIC pre-mRNA encoding the target protein. In cases, the retained intron is the most abundant intron in a population of RIC pre-mRNAs transcribed from the gene encoding the target protein in a cell, wherein the population of RIC pre-mRNAs comprises two or more retained introns. In cases, an antisense oligomer targeted to the most abundant intron in the population of RIC pre-mRNAs encoding the target protein induces splicing out of two or more retained introns in the population, including the retained intron to which the antisense oligomer is targeted or binds. In cases, a mature mRNA encoding the target protein is thereby produced. The terms "mature mRNA," and "fully-spliced mRNA," are used interchangeably herein to describe a fully processed mRNA encoding a target protein (e.g., mRNA that is exported from the nucleus into the cytoplasm and translated into target protein) or a fully processed functional RNA. The term "productive mRNA," also can be used to describe a fully processed mRNA encoding a target protein. In cases, the targeted region is in a retained intron that is the most abundant intron in a RIC pre-mRNA encoding the PRPF3 and/or PRPF8 protein. In cases, the most retained intron in a RIC pre-mRNA encoding the PRPF3 protein is intron 12. In cases, the most retained intron in a RIC pre-mRNA encoding the PRPF3 protein is intron 13. In some cases, the most retained intron in a RIC pre-mRNA encoding the PRPF8 protein is intron 31.

In cases, a retained intron is an intron that is identified as a retained intron based on a determination of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, or at least about 50%, retention. In cases, a retained intron is an intron that is identified as a retained intron based on a determination of about 5% to about 100%, about 5% to about 95%, about 5% to about 90%, about 5% to about 85%, about 5% to about 80%, about 5% to about 75%, about 5% to about 70%, about 5% to about 65%, about 5% to about 60%, about 5% to about 65%, about 5% to about 60%, about 5% to about 55%, about 5% to about 50%, about 5% to about 45%, about 5% to about 40%, about 5% to about 35%, about 5% to about 30%, about 5% to about 25%, about 5% to about 20%, about 5% to about 15%, about 10% to about 100%, about 10% to about 95%, about 10% to about 90%, about 10% to about 85%, about 10% to about 80%, about 10% to about 75%, about 10% to about 70%, about 10% to about 65%, about 10% to about 60%, about 10% to about 65%, about 10% to about 60%, about 10% to about 55%, about 10% to about 50%, about 10% to about 45%, about 10% to about 40%, about 10% to about 35%, about 10% to about 30%, about 10% to about 25%, about 10% to about 20%, about 15% to about 100%, about 15% to about 95%, about 15% to about 90%, about 15% to about 85%, about 15% to about 80%, about 15% to about 75%, about 15% to about 70%, about 15% to about 65%, about 15% to about 60%, about 15% to about 65%, about 15% to about 60%, about 15% to about 55%, about 15% to about 50%, about 15% to about 45%, about 15% to about 40%, about 15% to about 35%, about 15% to about 30%, about 15% to about 25%, about 20% to about 100%, about 20% to about 95%, about 20% to about 90%, about 20% to about 85%, about 20% to about 80%, about 20% to about 75%, about 20% to about 70%, about 20% to about 65%, about 20% to about 60%, about 20% to about 65%, about 20% to about 60%, about 20% to about 55%, about 20% to about 50%, about 20% to about 45%, about 20% to about 40%, about 20% to about 35%, about 20% to about 30%, about 25% to about 100%, about 25% to about 95%, about 25% to about 90%, about 25% to about 85%, about 25% to about 80%, about 25% to about 75%, about 25% to about 70%, about 25% to about 65%, about 25% to about 60%, about 25% to about 65%, about 25% to about 60%, about 25% to about 55%, about 25% to about 50%, about 25% to about 45%, about 25% to about 40%, or about 25% to about 35%, retention. ENCODE data (described by, e.g., Tilgner, et al., 2012, "Deep sequencing of subcellular RNA fractions shows splicing to be predominantly co-transcriptional in the human genome but inefficient for IncRNAs," Genome Research 22(9): 1616-25) can be used to aid in identifying retained introns.

As used herein, the term "comprise" or variations thereof such as "comprises" or "comprising" are to be read to indicate the inclusion of any recited feature (e.g. in the case of an antisense oligomer, a defined nucleobase sequence) but not the exclusion of any other features. Thus, as used herein, the term "comprising" is inclusive and does not exclude additional, unrecited features (e.g. in the case of an antisense oligomer, the presence of additional, unrecited nucleobases).

In cases of any of the compositions and methods provided herein, "comprising" may be replaced with "consisting essentially of" or "consisting of." The phrase "consisting essentially of' is used herein to require the specified feature(s) (e.g. nucleobase sequence) as well as those which do not materially affect the character or function of the present disclosure. As used herein, the term "consisting" is used to indicate the presence of the recited feature (e.g. nucleobase sequence) alone (so that in the case of an antisense oligomer consisting of a specified nucleobase sequence, the presence of additional, unrecited nucleobases is excluded).

In cases, the targeted region is in a retained intron that is the second most abundant intron in a population of RIC pre-mRNA encoding the PRPF3 or PRPF8 protein. For example, the second most abundant retained intron may be targeted rather than the most abundant retained intron due to the uniqueness of the nucleotide sequence of the second most abundant retained intron, ease of ASO design to target a particular nucleotide sequence, and/or amount of increase in protein production resulting from targeting the intron with an ASO. In cases, the retained intron is the second most abundant intron in a population of RIC pre-mRNAs transcribed from the gene encoding the target protein in a cell, wherein the population of RIC pre-mRNAs comprises two or more retained introns. In cases, an antisense oligomer targeted to the second most abundant intron in the population of RIC pre-mRNAs encoding the target protein induces splicing out of two or more retained introns in the population, including the retained intron to which the antisense oligomer is targeted or binds. In cases, fully-spliced (mature) RNA encoding the target protein is thereby produced. In cases, the second-most abundant retained intron in a population of RIC pre-mRNA encoding the PRPF3 protein is intron 12. In cases, the second-most abundant retained intron in a population of RIC pre-mRNA encoding the PRPF3 protein is intron 13.

In cases, an ASO is complementary to a targeted region that is within a non-retained intron in a RIC pre-mRNA. In cases, the targeted portion of the RIC pre-mRNA is within: the region +6 to +100 relative to the 5' splice site of the non-retained intron; or the region -16 to -100 relative to the 3' splice site of the non-retained intron. In cases, the targeted portion of the RIC pre-mRNA is within the region +100 relative to the 5' splice site of the non-retained intron to - 100 relative to the 3' splice site of the non-retained intron. As used to identify the location of a region or sequence, "within" is understood to include the residues at the positions recited. For example, a region +6 to +100 includes the residues at positions +6 and +100. In cases, fully-spliced (mature) RNA encoding the target protein is thereby produced.

In cases, the retained intron of the RIC pre-mRNA is an inefficiently spliced intron. As used herein, "inefficiently spliced" may refer to a relatively low frequency of splicing at a splice site adjacent to the retained intron (5' splice site or 3' splice site) as compared to the frequency of splicing at another splice site in the RIC pre-mRNA. The term "inefficiently spliced" may also refer to the relative rate or kinetics of splicing at a splice site, in which an "inefficiently spliced" intron may be spliced or removed at a slower rate as compared to another intron in a RIC pre-mRNA.

In cases, the 9-nucleotide sequence at -3e to -1e of the exon flanking the 5' splice site and +1 to +6 of the retained intron is identical to the corresponding wild-type sequence. In cases, the 16 nucleotide sequence at -15 to -1 of the retained intron and +1e of the exon flanking the 3' splice site is identical to the corresponding wild-type sequence. As used herein, the "wild-type sequence" refers to the nucleotide sequence for the PRPF3 or PRPF8 gene in the published reference genome deposited in the NCBI repository of biological and scientific information. As used herein, the "wild-type PRPF3 sequence" refers to the canonical sequence available at NCBI Gene ID 9129. As used herein, the "wild-type PRPF8 sequence" refers to the canonical sequence available at NCBI Gene ID 10594. Also used herein, a nucleotide position denoted with an "e" indicates the nucleotide is present in the sequence of an exon (e.g., the exon flanking the 5' splice site or the exon flanking the 3' splice site).

The methods involve contacting cells with an ASO that is complementary to a portion of a pre-mRNA encoding PRPF3 or PRPF8 protein, resulting in increased expression of the PRPF3 or PRPF8 protein, respectively. As used herein, "contacting" or administering to cells refers to any method of providing an ASO in immediate proximity with the cells such that the ASO and the cells interact. A cell that is contacted with an ASO will take up or transport the ASO into the cell. The method involves contacting a condition or disease-associated or condition or disease-relevant cell with any of the ASOs described herein. In some cases, the ASO may be further modified or attached (e.g., covalently attached) to another molecule to target the ASO to a cell type, enhance contact between the ASO and the condition or disease-associated or condition or disease-relevant cell, or enhance uptake of the ASO.

As used herein, the term "increasing protein production" or "increasing expression of a target protein" means enhancing the amount of protein that is translated from an mRNA in a cell. A "target protein" may be any protein for which increased expression/production is desired.

In cases, contacting a cell that expresses a PRPF3 or PRPF8 RIC pre-mRNA with an ASO that is complementary to a targeted portion of the PRPF3 or PRPF8 RIC pre-mRNA transcript results in a measurable increase in the amount of the PRPF3 or PRPF8 protein (e.g., a target protein) encoded by the pre-mRNA. Methods of measuring or detecting production of a protein will be evident to one of skill in the art and include any known method, for example, Western blotting, flow cytometry, immunofluorescence microscopy, and ELISA.

In cases, contacting cells with an ASO that is complementary to a targeted portion of a PRPF3 and/or PRPF8 RIC pre-mRNA transcript results in an increase in the amount of PRPF3 and/or PRPF8 protein produced by at least 10, 20, 30, 40, 50, 60, 80, 100, 150, 200, 250, 300, 350, 400, 450, 500, or 1000%, compared to the amount of the protein produced by a cell in the absence of the ASO/absence of treatment. In cases, the total amount of PRPF3 or PRPF8 protein produced by the cell to which the antisense oligomer was contacted is increased about 1.1 to about 10-fold, about 1.5 to about 10-fold, about 2 to about 10-fold, about 3 to about 10-fold, about 4 to about 10-fold, about 1.1 to about 5-fold, about 1.1 to about 6-fold, about 1.1 to about 7-fold, about 1.1 to about 8-fold, about 1.1 to about 9-fold, about 2 to about 5-fold, about 2 to about 6-fold, about 2 to about 7-fold, about 2 to about 8-fold, about 2 to about 9-fold, about 3 to about 6-fold, about 3 to about 7-fold, about 3 to about 8-fold, about 3 to about 9-fold, about 4 to about 7-fold, about 4 to about 8-fold, about 4 to about 9-fold, at least about 1.1-fold, at least about 1.5-fold, at least about 2-fold, at least about 2.5-fold, at least about 3-fold, at least about 3.5-fold, at least about 4-fold, at least about 5-fold, or at least about 10-fold, compared to the amount of target protein produced by an control compound. A control compound can be, for example, an oligonucleotide that is not complementary to the targeted portion of the RIC pre-mRNA.

In some cases, contacting cells with an ASO that is complementary to a targeted portion of a PRPF3 or PRPF8 RIC pre-mRNA transcript results in an increase in the amount of mRNA encoding PRPF3 or PRPF8, including the mature mRNA encoding the target protein. In some cases, the amount of mRNA encoding PRPF3 or PRPF8 protein, or the mature mRNA encoding the PRPF3 or PRPF8 protein, is increased by at least 10, 20, 30, 40, 50, 60, 80, 100, 150, 200, 250, 300, 350, 400, 450, 500, or 1000%, compared to the amount of the protein produced by a cell in the absence of the ASO/absence of treatment. In cases, the total amount of the mRNA encoding PRPF3 or PRPF8 protein, or the mature mRNA encoding PRPF3 or PRPF8 protein produced in the cell to which the antisense oligomer was contacted is increased about 1.1 to about 10-fold, about 1.5 to about 10-fold, about 2 to about 10-fold, about 3 to about 10-fold, about 4 to about 10-fold, about 1.1 to about 5-fold, about 1.1 to about 6-fold, about 1.1 to about 7-fold, about 1.1 to about 8-fold, about 1.1 to about 9-fold, about 2 to about 5-fold, about 2 to about 6-fold, about 2 to about 7-fold, about 2 to about 8-fold, about 2 to about 9-fold, about 3 to about 6-fold, about 3 to about 7-fold, about 3 to about 8-fold, about 3 to about 9-fold, about 4 to about 7-fold, about 4 to about 8-fold, about 4 to about 9-fold, at least about 1.1-fold, at least about 1.5-fold, at least about 2-fold, at least about 2.5-fold, at least about 3-fold, at least about 3.5-fold, at least about 4-fold, at least about 5-fold, or at least about 10-fold compared to the amount of mature RNA produced in an untreated cell, e.g., an untreated cell or a cell treated with a control compound. A control compound can be, for example, an oligonucleotide that is not complementary to the targeted portion of the PRPF3 or PRPF8 RIC pre-mRNA.

Constitutive Splicing of a Retained Intron from a RIC pre-mRNA

The methods and antisense oligonucleotide compositions provided herein are useful for increasing the expression of PRPF3 or PRPF8 protein in cells, for example, in a subject having RP caused by a deficiency in the amount or activity of PRPF3 or PRPF8 protein, by increasing the level of mRNA encoding PRPF3 or PRPF8 protein, or the mature mRNA encoding PRPF3 or PRPF8 protein. In particular, the methods and compositions as described herein induce the constitutive splicing of a retained intron from a PRPF3 or PRPF8 RIC pre-mRNA transcript encoding PRPF3 or PRPF8 protein, thereby increasing the level of mRNA encoding PRPF3 or PRPF8 protein, or the mature mRNA encoding PRPF3 or PRPF8 protein and increasing the expression of PRPF3 or PRPF8 protein.

Constitutive splicing of a retained intron from a RIC pre-mRNA correctly removes the retained intron from the RIC pre-mRNA, wherein the retained intron has wild-type splice sequences. Constitutive splicing, as used herein, does not encompass splicing of a retained intron from a RIC pre-mRNA transcribed from a gene or allele having a mutation that causes alternative splicing or aberrant splicing of a pre-mRNA transcribed from the gene or allele. For example, constitutive splicing of a retained intron, as induced using the methods and antisense oligonucleotides provided herein, does not correct aberrant splicing in or influence alternative splicing of a pre-mRNA to result in an increased expression of a target protein or functional RNA.

In some cases, constitutive splicing correctly removes a retained intron from a PRPF3 or PRPF8 RIC pre-mRNA, wherein the PRPF3 or PRPF8 RIC pre-mRNA is transcribed from a wild-type gene or allele, or a polymorphic gene or allele, that encodes a fully-functional target protein or functional RNA, and wherein the gene or allele does not have a mutation that causes alternative splicing or aberrant splicing of the retained intron.

In some cases, constitutive splicing of a retained intron from a PRPF3 or PRPF8 RIC pre-mRNA encoding PRPF3 or PRPF8 protein correctly removes a retained intron from a PRPF3 or PRPF8 RIC pre-mRNA encoding PRPF3 or PRPF8 protein, wherein the PRPF3 or PRPF8 RIC pre-mRNA is transcribed from a gene or allele from which the target gene or functional RNA is produced at a reduced level compared to production from a wild-type allele, and wherein the gene or allele does not have a mutation that causes alternative splicing or aberrant splicing of the retained intron. In these cases, the correct removal of the constitutively spliced retained intron results in production of target protein or functional RNA that is functional when compared to an equivalent wild-type protein or functional RNA.

In other cases, constitutive splicing correctly removes a retained intron from a PRPF3 or PRPF8 RIC pre-mRNA, wherein the PRPF3 or PRPF8 RIC pre-mRNA is transcribed from a gene or allele that encodes a target protein or functional RNA produced in a form having reduced function compared to an equivalent wild-type protein or functional RNA, and wherein the gene or allele does not have a mutation that causes alternative splicing or aberrant splicing of the retained intron. In these cases, the correct removal of the constitutively spliced retained intron results in production of partially functional target protein, or functional RNA that is partially functional when compared to an equivalent wild-type protein or functional RNA.

"Correct removal" of the retained intron by constitutive splicing refers to removal of the entire intron, without removal of any part of an exon.

In some cases, an antisense oligomer as described herein or used in any method described herein does not increase the amount of mRNA encoding PRPF3 or PRPF8 protein or the amount of PRPF3 or PRPF8 protein by modulating alternative splicing or aberrant splicing of a pre-mRNA transcribed from the PRPF3 or PRPF8 gene. Modulation of alternative splicing or aberrant splicing can be measured using any known method for analyzing the sequence and length of RNA species, e.g., by RT-PCR and using methods described elsewhere herein and in the literature. In some cases, modulation of alternative or aberrant splicing is determined based on an increase or decrease in the amount of the spliced species of interest of at least 10% or 1.1-fold. In some cases, modulation is determined based on an increase or decrease at a level that is at least 10% to 100% or 1.1 to 10-fold, as described herein regarding determining an increase in mRNA encoding PRPF3 or PRPF8 protein in the methods of the disclosure.

In cases, the method is a method wherein the PRPF3 or PRPF8 RIC pre-mRNA was produced by partial splicing of a wild-type PRPF3 or PRPF8 pre-mRNA. In cases, the method is a method wherein the PRPF3 or PRPF8 RIC pre-mRNA was produced by partial splicing of a full-length wild-type PRPF3 or PRPF8 pre-mRNA. In cases, the PRPF3 or PRPF8 RIC pre-mRNA was produced by partial splicing of a full-length PRPF3 or PRPF8 pre-mRNA. In these cases, a full-length PRPF3 or PRPF8 pre-mRNA may have a polymorphism in a splice site of the retained intron that does not impair correct splicing of the retained intron as compared to splicing of the retained intron having the wild-type splice site sequence.

In cases, the mRNA encoding PRPF3 or PRPF8 protein is a full-length mature mRNA, or a wild-type mature mRNA. In these cases, a full-length mature mRNA may have a polymorphism that does not affect the activity of the target protein or the functional RNA encoded by the mature mRNA, as compared to the activity of PRPF3 or PRPF8 protein encoded by the wild-type mature mRNA.

Antisense Oligomers

One aspect of the present disclosure is a composition comprising antisense oligomers that enhances splicing by binding to a targeted portion of a PRPF3 or PRPF8 RIC pre-mRNA. As used herein, the terms "ASO" and "antisense oligomer" are used interchangeably and refer to an oligomer such as a polynucleotide, comprising nucleobases, that hybridizes to a target nucleic acid (e.g., a PRPF3 or PRPF8 RIC pre-mRNA) sequence by Watson-Crick base pairing or wobble base pairing (G-U). The ASO may have exact sequence complementary to the target sequence or near complementarity (e.g., sufficient complementarity to bind the target sequence and enhancing splicing at a splice site). ASOs are designed so that they bind (hybridize) to a target nucleic acid (e.g., a targeted portion of a pre-mRNA transcript) and remain hybridized under physiological conditions. Typically, if they hybridize to a site other than the intended (targeted) nucleic acid sequence, they hybridize to a limited number of sequences that are not a target nucleic acid (to a few sites other than a target nucleic acid). Design of an ASO can take into consideration the occurrence of the nucleic acid sequence of the targeted portion of the pre-mRNA transcript or a sufficiently similar nucleic acid sequence in other locations in the genome or cellular pre-mRNA or transcriptome, such that the likelihood the ASO will bind other sites and cause "off-target" effects is limited. Any antisense oligomers known in the art, for example in PCT Application No. PCT/US2014/054151 , published as WO 2015/035091 , titled "Reducing Nonsense-Mediated mRNA Decay," can be used to practice the methods described herein.

In some cases, ASOs "specifically hybridize" to or are "specific" to a target nucleic acid or a targeted portion of a RIC pre-mRNA. Typically such hybridization occurs with a Tm substantially greater than 37°C, preferably at least 50°C, and typically between 60°C to approximately 90°C. Such hybridization preferably corresponds to stringent hybridization conditions. At a given ionic strength and pH, the Tm is the temperature at which 50% of a target sequence hybridizes to a complementary oligonucleotide.

Oligomers, such as oligonucleotides, are "complementary" to one another when hybridization occurs in an antiparallel configuration between two single-stranded polynucleotides. A double-stranded polynucleotide can be "complementary" to another polynucleotide, if hybridization can occur between one of the strands of the first polynucleotide and the second. Complementarity (the degree to which one polynucleotide is complementary with another) is quantifiable in terms of the proportion (e.g., the percentage) of bases in opposing strands that are expected to form hydrogen bonds with each other, according to generally accepted base-pairing rules. The sequence of an antisense oligomer (ASO) need not be 100% complementary to that of its target nucleic acid to hybridize. In certain cases, ASOs can comprise at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence complementarity to a target region within the target nucleic acid sequence to which they are targeted. For example, an ASO in which 18 of 20 nucleobases of the oligomeric compound are complementary to a target region, and would therefore specifically hybridize, would represent 90 percent complementarity. In this example, the remaining noncomplementary nucleobases may be clustered together or interspersed with complementary nucleobases and need not be contiguous to each other or to complementary nucleobases. Percent complementarity of an ASO with a region of a target nucleic acid can be determined routinely using BLAST programs (basic local alignment search tools) and PowerBLAST programs known in the art (Altschul et al., J. Mol. Biol., 1990, 215, 403-410; Zhang and Madden, Genome Res., 1997, 7, 649-656).

An ASO need not hybridize to all nucleobases in a target sequence and the nucleobases to which it does hybridize may be contiguous or noncontiguous. ASOs may hybridize over one or more segments of a pre-mRNA transcript, such that intervening or adjacent segments are not involved in the hybridization event (e.g., a loop structure or hairpin structure may be formed). In certain cases, an ASO hybridizes to noncontiguous nucleobases in a target pre-mRNA transcript. For example, an ASO can hybridize to nucleobases in a pre-mRNA transcript that are separated by one or more nucleobase(s) to which the ASO does not hybridize.

The ASOs described herein comprise nucleobases that are complementary to nucleobases present in a target portion of a RIC pre-mRNA. The term ASO embodies oligonucleotides and any other oligomeric molecule that comprises nucleobases capable of hybridizing to a complementary nucleobase on a target mRNA but does not comprise a sugar moiety, such as a peptide nucleic acid (PNA). The ASOs may comprise naturally-occurring nucleotides, nucleotide analogs, modified nucleotides, or any combination of two or three of the preceding. The term "naturally occurring nucleotides" includes deoxyribonucleotides and ribonucleotides. The term "modified nucleotides" includes nucleotides with modified or substituted sugar groups and/or having a modified backbone. In some cases, all of the nucleotides of the ASO are modified nucleotides. Chemical modifications of ASOs or components of ASOs that are compatible with the methods and compositions described herein will be evident to one of skill in the art and can be found, for example, in U.S. Patent No. 8,258,109 B2 , U.S. Patent No. 5,656,612 , U.S. Patent Publication No. 2012/0190728 , and Dias and Stein, Mol. Cancer Ther. 2002, 1 , 347-355.

The nucleobase of an ASO may be any naturally occurring, unmodified nucleobase such as adenine, guanine, cytosine, thymine and uracil, or any synthetic or modified nucleobase that is sufficiently similar to an unmodified nucleobase such that it is capable of hydrogen bonding with a nucleobase present on a target pre-mRNA. Examples of modified nucleobases include, without limitation, hypoxanthine, xanthine, 7-methylguanine, 5,6-dihydrouracil, 5-methylcytosine, and 5-hydroxymethoylcytosine.

The ASOs described herein also comprise a backbone structure that connects the components of an oligomer. The term "backbone structure" and "oligomer linkages" may be used interchangeably and refer to the connection between monomers of the ASO. In naturally occurring oligonucleotides, the backbone comprises a 3'-5' phosphodiester linkage connecting sugar moieties of the oligomer. The backbone structure or oligomer linkages of the ASOs described herein may include (but are not limited to) phosphorothioate, phosphorodithioate, phosphoroselenoate, phosphorodiselenoate, phosphoroanilothioate, phosphoraniladate, phosphoramidate, and the like. See e.g., LaPlanche et al., Nucleic Acids Res. 14:9081 (1986); Stec et al., J. Am. Chem. Soc. 106:6077 (1984), Stein et al., Nucleic Acids Res. 16:3209 (1988), Zon et al., Anti Cancer Drug Design 6:539 (1991); Zon et al., Oligonucleotides and Analogues: A Practical Approach, pp. 87-108 (F. Eckstein, Ed., Oxford University Press, Oxford England (1991)); Stec et al., U.S. Pat. No. 5,151,510 ; Uhlmann and Peyman, Chemical Reviews 90:543 (1990). In some cases, the backbone structure of the ASO does not contain phosphorous but rather contains peptide bonds, for example in a peptide nucleic acid (PNA), or linking groups including carbamate, amides, and linear and cyclic hydrocarbon groups. In some cases, the backbone modification is a phosphothioate linkage. In some cases, the backbone modification is a phosphoramidate linkage.

In cases, the stereochemistry at each of the phosphorus internucleotide linkages of the ASO backbone is random. In cases, the stereochemistry at each of the phosphorus internucleotide linkages of the ASO backbone is controlled and is not random. For example, U.S. Pat. App. Pub. No. 2014/0194610 , "Methods for the Synthesis of Functionalized Nucleic Acids," incorporated herein by reference, describes methods for independently selecting the handedness of chirality at each phosphorous atom in a nucleic acid oligomer. An ASO used in the methods of the disclosure, including, but not limited to, any of the ASOs set forth herein in Table 1, comprises an ASO having phosphorus internucleotide linkages that are not random. A composition used in the methods of the disclosure comprises a pure diastereomeric ASO. In cases, a composition used in the methods of the disclosure comprises an ASO that has diastereomeric purity of at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, about 100%, about 90% to about 100%, about 91% to about 100%, about 92% to about 100%, about 93% to about 100%, about 94% to about 100%, about 95% to about 100%, about 96% to about 100%, about 97% to about 100%, about 98% to about 100% , or about 99% to about 100%.

In cases, the ASO has a nonrandom mixture of Rp and Sp configurations at its phosphorus internucleotide linkages. For example, it has been suggested that a mix of Rp and Sp is required in antisense oligonucleotides to achieve a balance between good activity and nuclease stability (Wan, et al., 2014, "Synthesis, biophysical properties and biological activity of second generation antisense oligonucleotides containing chiral phosphorothioate linkages," Nucleic Acids Research 42(22): 13456-13468, incorporated herein by reference). In cases, an ASO used in the methods of the disclosure, including, but not limited to, any of the ASOs set forth herein in Table 1, comprises about 5-100% Rp, at least about 5% Rp, at least about 10% Rp, at least about 15% Rp, at least about 20% Rp, at least about 25% Rp, at least about 30% Rp, at least about 35% Rp, at least about 40% Rp, at least about 45% Rp, at least about 50% Rp, at least about 55% Rp, at least about 60% Rp, at least about 65% Rp, at least about 70% Rp, at least about 75% Rp, at least about 80% Rp, at least about 85% Rp, at least about 90% Rp, or at least about 95% Rp, with the remainder Sp, or about 100% Rp. In cases, an ASO used in the methods of the disclosure, including, but not limited to, any of the ASOs set forth herein in Table 1, comprises about 10% to about 100% Rp, about 15% to about 100% Rp, about 20% to about 100% Rp, about 25% to about 100% Rp, about 30% to about 100% Rp, about 35% to about 100% Rp, about 40% to about 100% Rp, about 45% to about 100% Rp, about 50% to about 100% Rp, about 55% to about 100% Rp, about 60% to about 100% Rp, about 65% to about 100% Rp, about 70% to about 100% Rp, about 75% to about 100% Rp, about 80% to about 100% Rp, about 85% to about 100% Rp, about 90% to about 100% Rp, or about 95% to about 100% Rp, about 20% to about 80% Rp, about 25% to about 75% Rp, about 30% to about 70% Rp, about 40% to about 60% Rp, or about 45% to about 55% Rp, with the remainder Sp.

In cases, an ASO used in the methods of the disclosure, including, but not limited to, any of the ASOs set forth herein in Table 1, comprises about 5-100% Sp, at least about 5% Sp, at least about 10% Sp, at least about 15% Sp, at least about 20% Sp, at least about 25% Sp, at least about 30% Sp, at least about 35% Sp, at least about 40% Sp, at least about 45% Sp, at least about 50% Sp, at least about 55% Sp, at least about 60% Sp, at least about 65% Sp, at least about 70% Sp, at least about 75% Sp, at least about 80% Sp, at least about 85% Sp, at least about 90% Sp, or at least about 95% Sp, with the remainder Rp, or about 100% Sp. In cases, an ASO used in the methods of the disclosure, including, but not limited to, any of the ASOs set forth herein in Table 1, comprises about 10% to about 100% Sp, about 15% to about 100% Sp, about 20% to about 100% Sp, about 25% to about 100% Sp, about 30% to about 100% Sp, about 35% to about 100% Sp, about 40% to about 100% Sp, about 45% to about 100% Sp, about 50% to about 100% Sp, about 55% to about 100% Sp, about 60% to about 100% Sp, about 65% to about 100% Sp, about 70% to about 100% Sp, about 75% to about 100% Sp, about 80% to about 100% Sp, about 85% to about 100% Sp, about 90% to about 100% Sp, or about 95% to about 100% Sp, about 20% to about 80% Sp, about 25% to about 75% Sp, about 30% to about 70% Sp, about 40% to about 60% Sp, or about 45% to about 55% Sp, with the remainder Rp.

Any of the ASOs described herein may contain a sugar moiety that comprises ribose or deoxyribose, as present in naturally occurring nucleotides, or a modified sugar moiety or sugar analog, including a morpholine ring. Non-limiting examples of modified sugar moieties include 2' substitutions such as 2'-O-methyl (2'-O-Me), 2'-O-methoxyethyl (2'MOE), 2'-O-aminoethyl, 2'F; N3'->P5' phosphoramidate, 2'dimethylaminooxyethoxy, 2'dimethylaminoethoxyethoxy, 2'-guanidinidium, 2'-O-guanidinium ethyl, carbamate modified sugars, and bicyclic modified sugars. In some cases, the sugar moiety modification is selected from 2'-O-Me, 2'F, and 2'MOE. In some cases, the sugar moiety modification is an extra bridge bond, such as in a locked nucleic acid (LNA). In some cases the sugar analog contains a morpholine ring, such as phosphorodiamidate morpholino (PMO). In some cases, the sugar moiety comprises a ribofuransyl or 2'deoxyribofuransyl modification. In some cases, the sugar moiety comprises 2'4'-constrained 2'O-methyloxyethyl (cMOE) modifications. In some cases, the sugar moiety comprises cEt 2', 4' constrained 2'-O ethyl BNA modifications. In some cases, the sugar moiety comprises tricycloDNA (tcDNA) modifications. In some cases, the sugar moiety comprises ethylene nucleic acid (ENA) modifications. In some cases, the sugar moiety comprises MCE modifications. Modifications are known in the art and described in the literature, e.g., by Jarver, et al., 2014, "A Chemical View of Oligonucleotides for Exon Skipping and Related Drug Applications," Nucleic Acid Therapeutics 24(1): 37-47.

In some examples, each monomer of the ASO is modified in the same way, for example each linkage of the backbone of the ASO comprises a phosphorothioate linkage or each ribose sugar moiety comprises a 2'O-methyl modification. Such modifications that are present on each of the monomer components of an ASO are referred to as "uniform modifications." In some examples, a combination of different modifications may be desired, for example, an ASO may comprise a combination of phosphorodiamidate linkages and sugar moieties comprising morpholine rings (morpholinos). Combinations of different modifications to an ASO are referred to as "mixed modifications" or "mixed chemistries."

In some cases, the ASO comprises one or more backbone modification. In some cases, the ASO comprises one or more sugar moiety modification. In some cases, the ASO comprises one or more backbone modification and one or more sugar moiety modification. In some cases, the ASO comprises 2'MOE modifications and a phosphorothioate backbone. In some cases, the ASO comprises a phosphorodiamidate morpholino (PMO). In some cases, the ASO comprises a peptide nucleic acid (PNA). Any of the ASOs or any component of an ASO (e.g., a nucleobase, sugar moiety, backbone) described herein may be modified in order to achieve desired properties or activities of the ASO or reduce undesired properties or activities of the ASO. For example, an ASO or one or more component of any ASO may be modified to enhance binding affinity to a target sequence on a pre-mRNA transcript; reduce binding to any non-target sequence; reduce degradation by cellular nucleases (i.e., RNase H); improve uptake of the ASO into a cell and/or into the nucleus of a cell; alter the pharmacokinetics or pharmacodynamics of the ASO; and modulate the half-life of the ASO.

In some cases, the ASOs are comprised of 2'-O-(2-methoxyethyl) (MOE) phosphorothioate-modified nucleotides. ASOs comprised of such nucleotides are especially well-suited to the methods disclosed herein; oligomers having such modifications have been shown to have significantly enhanced resistance to nuclease degradation and increased bioavailability, making them suitable, for example, for oral delivery in some cases described herein. See e.g., Geary et al., J Pharmacol Exp Ther. 2001; 296(3):890-7; Geary et al., J Pharmacol Exp Ther. 2001; 296(3):898-904.

Methods of synthesizing ASOs will be known to one of skill in the art. Alternatively or in addition, ASOs may be obtained from a commercial source.

Unless specified otherwise, the left-hand end of single-stranded nucleic acid (e.g., pre-mRNA transcript, oligonucleotide, ASO, etc.) sequences is the 5' end and the left-hand direction of single or double-stranded nucleic acid sequences is referred to as the 5' direction. Similarly, the right-hand end or direction of a nucleic acid sequence (single or double stranded) is the 3' end or direction. Generally, a region or sequence that is 5' to a reference point in a nucleic acid is referred to as "upstream," and a region or sequence that is 3' to a reference point in a nucleic acid is referred to as "downstream." Generally, the 5' direction or end of an mRNA is where the initiation or start codon is located, while the 3' end or direction is where the termination codon is located. In some aspects, nucleotides that are upstream of a reference point in a nucleic acid may be designated by a negative number, while nucleotides that are downstream of a reference point may be designated by a positive number. For example, a reference point (e.g., an exon-exon junction in mRNA) may be designated as the "zero" site, and a nucleotide that is directly adjacent and upstream of the reference point is designated "minus one," e.g., "-1," while a nucleotide that is directly adjacent and downstream of the reference point is designated "plus one," e.g., "+1."

In other cases, the ASOs are complementary to (and bind to) a targeted portion of a PRPF3 or PRPF8 RIC pre-mRNA that is downstream (in the 3' direction) of the 5' splice site of the retained intron in a PRPF3 or PRPF8 RIC pre-mRNA (e.g., the direction designated by positive numbers relative to the 5' splice site) (Figure 1). In some cases, the ASOs are complementary to a targeted portion of the PRPF3 or PRPF8 RIC pre-mRNA that is within the region +6 to +100 relative to the 5' splice site of the retained intron. In some cases, the ASO is not complementary to nucleotides +1 to +5 relative to the 5' splice site (the first five nucleotides located downstream of the 5' splice site). In some cases, the ASOs may be complementary to a targeted portion of a PRPF3 or PRPF8 RIC pre-mRNA that is within the region between nucleotides +6 and +50 relative to the 5' splice site of the retained intron. In some aspects, the ASOs are complementary to a targeted portion that is within the region +6 to +90, +6 to +80, +6 to +70, +6 to +60, +6 to +50, +6 to +40, +6 to +30, or +6 to +20 relative to 5' splice site of the retained intron.

In some cases, the ASOs are complementary to a targeted region of a PRPF3 or PRPF8 RIC pre-mRNA that is upstream (5' relative) of the 3' splice site of the retained intron in a PRPF3 or PRPF8 RIC pre-mRNA (e.g., in the direction designated by negative numbers) (Figure 1). In some cases, the ASOs are complementary to a targeted portion of the PRPF3 or PRPF8 RIC pre-mRNA that is within the region -16 to -100 relative to the 3' splice site of the retained intron. In some cases, the ASO is not complementary to nucleotides -1 to -15 relative to the 3' splice site (the first 15 nucleotides located upstream of the 3' splice site). In some cases, the ASOs are complementary to a targeted portion of the PRPF3 or PRPF8 RIC pre-mRNA that is within the region -16 to -50 relative to the 3' splice site of the retained intron. In some aspects, the ASOs are complementary to a targeted portion that is within the region -16 to -90, -16 to -80, -16 to -70, -16 to -60, -16 to -50, -16 to -40, or -16 to -30 relative to 3' splice site of the retained intron.

In cases, the targeted portion of the PRPF3 or PRPF8 RIC pre-mRNA is within the region +100 relative to the 5' splice site of the retained intron to -100 relative to the 3' splice site of the retained intron.

In some cases, the ASOs are complementary to a targeted portion of a PRPF3 or PRPF8 RIC pre-mRNA that is within the exon flanking the 5' splice site (upstream) of the retained intron (Figure 1). In some cases, the ASOs are complementary to a targeted portion of the PRPF3 or PRPF8 RIC pre-mRNA that is within the region +2e to -4e in the exon flanking the 5' splice site of the retained intron. In some cases, the ASOs are not complementary to nucleotides -1e to -3e relative to the 5' splice site of the retained intron. In some cases, the ASOs are complementary to a targeted portion of the PRPF3 or PRPF8 RIC pre-mRNA that is within the region -4e to -100e, -4e to -90e, -4e to -80e, -4e to -70e, -4e to -60e, -4e to -50e, -4 to -40e, - 4e to -30e, or -4e to -20e relative to the 5' splice site of the retained intron.

In some cases, the ASOs are complementary to a targeted portion of a PRPF3 or PRPF8 RIC pre-mRNA that is within the exon flanking the 3' splice site (downstream) of the retained intron (Figure 1). In some cases, the ASOs are complementary to a targeted portion to the PRPF3 or PRPF8 RIC pre-mRNA that is within the region +2e to -4e in the exon flanking the 3' splice site of the retained intron. In some cases, the ASOs are not complementary to nucleotide +1e relative to the 3' splice site of the retained intron. In some cases, the ASOs are complementary to a targeted portion of the PRPF3 or PRPF8 RIC pre-mRNA that is within the region+2e to +100e, +2e to +90e, +2e to +80e, +2e to +70e, +2e to +60e, +2e to +50e, +2e to +40e, +2e to +30e, or +2 to +20e relative to the 3' splice site of the retained intron. The ASOs may be of any length suitable for specific binding and effective enhancement of splicing. In some cases, the ASOs consist of 8 to 50 nucleobases. For example, the ASO may be 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 40, 45, or 50 nucleobases in length. In some cases, the ASOs consist of more than 50 nucleobases. In some cases, the ASO is from 8 to 50 nucleobases, 8 to 40 nucleobases, 8 to 35 nucleobases, 8 to 30 nucleobases, 8 to 25 nucleobases, 8 to 20 nucleobases, 8 to 15 nucleobases, 9 to 50 nucleobases, 9 to 40 nucleobases, 9 to 35 nucleobases, 9 to 30 nucleobases, 9 to 25 nucleobases, 9 to 20 nucleobases, 9 to 15 nucleobases, 10 to 50 nucleobases, 10 to 40 nucleobases, 10 to 35 nucleobases, 10 to 30 nucleobases, 10 to 25 nucleobases, 10 to 20 nucleobases, 10 to 15 nucleobases, 11 to 50 nucleobases, 11 to 40 nucleobases, 11 to 35 nucleobases, 11 to 30 nucleobases, 11 to 25 nucleobases, 11 to 20 nucleobases, 11 to 15 nucleobases, 12 to 50 nucleobases, 12 to 40 nucleobases, 12 to 35 nucleobases, 12 to 30 nucleobases, 12 to 25 nucleobases, 12 to 20 nucleobases, 12 to 15 nucleobases, 13 to 50 nucleobases, 13 to 40 nucleobases, 13 to 35 nucleobases, 13 to 30 nucleobases, 13 to 25 nucleobases, 13 to 20 nucleobases, 14 to 50 nucleobases, 14 to 40 nucleobases, 14 to 35 nucleobases, 14 to 30 nucleobases, 14 to 25 nucleobases, 14 to 20 nucleobases, 15 to 50 nucleobases, 15 to 40 nucleobases, 15 to 35 nucleobases, 15 to 30 nucleobases, 15 to 25 nucleobases, 15 to 20 nucleobases, 20 to 50 nucleobases, 20 to 40 nucleobases, 20 to 35 nucleobases, 20 to 30 nucleobases, 20 to 25 nucleobases, 25 to 50 nucleobases, 25 to 40 nucleobases, 25 to 35 nucleobases, or 25 to 30 nucleobases in length. In some cases, the ASOs are 18 nucleotides in length. In some cases, the ASOs are 15 nucleotides in length. In some cases, the ASOs are 25 nucleotides in length.

In some cases, two or more ASOs with different chemistries but complementary to the same targeted portion of the RIC pre-mRNA are used. In some cases, two or more ASOs that are complementary to different targeted portions of the RIC pre-mRNA are used.

In cases, the antisense oligonucleotides of the disclosure are chemically linked to one or more moieties or conjugates, e.g., a targeting moiety or other conjugate that enhances the activity or cellular uptake of the oligonucleotide. Such moieties include, but are not limited to, a lipid moiety, e.g., as a cholesterol moiety, a cholesteryl moiety, an aliphatic chain, e.g., dodecandiol or undecyl residues, a polyamine or a polyethylene glycol chain, or adamantane acetic acid. Oligonucleotides comprising lipophilic moieties, and preparation methods have been described in the published literature. In cases, the antisense oligonucleotide is conjugated with a moiety including, but not limited to, an abasic nucleotide, a polyether, a polyamine, a polyamide, a peptides, a carbohydrate, e.g., N-acetylgalactosamine (GalNAc), N-Ac-Glucosamine (GluNAc), or mannose (e.g., mannose-6-phosphate), a lipid, or a polyhydrocarbon compound. Conjugates can be linked to one or more of any nucleotides comprising the antisense oligonucleotide at any of several positions on the sugar, base or phosphate group, as understood in the art and described in the literature, e.g., using a linker. Linkers can include a bivalent or trivalent branched linker. In cases, the conjugate is attached to the 3' end of the antisense oligonucleotide. Methods of preparing oligonucleotide conjugates are described, e.g., in U.S. Pat. No. 8,450,467 , "Carbohydrate conjugates as delivery agents for oligonucleotides,".

In some cases, the nucleic acid to be targeted by an ASO is a PRPF3 or PRPF8 RIC pre-mRNA expressed in a cell, such as a eukaryotic cell. In some cases, the term "cell" may refer to a population of cells. In some cases, the cell is in a subject. In some cases, the cell is isolated from a subject. In some cases, the cell is ex vivo. In some cases, the cell is a condition or disease-relevant cell or a cell line. In some cases, the cell is in vitro (e.g., in cell culture).

Pharmaceutical Compositions

Pharmaceutical compositions or formulations comprising the antisense oligonucleotide of the described compositions and for use in any of the described methods can be prepared according to conventional techniques well known in the pharmaceutical industry and described in the published literature. In cases, a pharmaceutical composition or formulation for treating a subject comprises an effective amount of any antisense oligomer as described above, or a pharmaceutically acceptable salt, solvate, hydrate or ester thereof, and a pharmaceutically acceptable diluent. The antisense oligomer of a pharmaceutical formulation may further comprise a pharmaceutically acceptable excipient, diluent or carrier.

Pharmaceutically acceptable salts are suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, etc., and are commensurate with a reasonable benefit/risk ratio. (See, e.g., S. M. Berge, et al., J. Pharmaceutical Sciences, 66: 1-19 (1977), incorporated herein by reference for this purpose. The salts can be prepared in situ during the final isolation and purification of the compounds, or separately by reacting the free base function with a suitable organic acid. Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other documented methodologies such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and aryl sulfonate.

In cases, the compositions are formulated into any of many possible dosage forms such as, but not limited to, tablets, capsules, gel capsules, liquid syrups, soft gels, suppositories, and enemas. In cases, the compositions are formulated as suspensions in aqueous, non-aqueous or mixed media. Aqueous suspensions may further contain substances that increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers. In cases, a pharmaceutical formulation or composition of the present disclosure includes, but is not limited to, a solution, emulsion, microemulsion, foam or liposome-containing formulation (e.g., cationic or noncationic liposomes).

The pharmaceutical composition or formulation of the present disclosure may comprise one or more penetration enhancer, carrier, excipients or other active or inactive ingredients as appropriate and well known to those of skill in the art or described in the published literature. In cases, liposomes also include sterically stabilized liposomes, e.g., liposomes comprising one or more specialized lipids. These specialized lipids result in liposomes with enhanced circulation lifetimes. In cases, a sterically stabilized liposome comprises one or more glycolipids or is derivatized with one or more hydrophilic polymers, such as a polyethylene glycol (PEG) moiety. In cases, a surfactant is included in the pharmaceutical formulation or compositions. The use of surfactants in drug products, formulations and emulsions is well known in the art. In cases, the present disclosure employs a penetration enhancer to effect the efficient delivery of the antisense oligonucleotide, e.g., to aid diffusion across cell membranes and /or enhance the permeability of a lipophilic drug. In cases, the penetration enhancer is a surfactant, fatty acid, bile salt, chelating agent, or non-chelating nonsurfactant.

In cases, the pharmaceutical formulation comprises multiple antisense oligonucleotides. In cases, the antisense oligonucleotide is administered in combination with another drug or therapeutic agent. In cases, the antisense oligonucleotide is administered with one or more agents capable of promoting penetration of the subject antisense oligonucleotide across the blood-brain barrier by any method known in the art. For example, delivery of agents by administration of an adenovirus vector to motor neurons in muscle tissue is described in U.S. Pat. No. 6,632,427 , "Adenoviral-vector-mediated gene transfer into medullary motor neurons," incorporated herein by reference. Delivery of vectors directly to the brain, e.g., the striatum, the thalamus, the hippocampus, or the substantia nigra, is described, e.g., in U.S. Pat. No. 6,756,523 , "Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system particularly in brain," incorporated herein by reference.

In cases, the antisense oligonucleotides are linked or conjugated with agents that provide desirable pharmaceutical or pharmacodynamic properties. In cases, the antisense oligonucleotide is coupled to a substance, known in the art to promote penetration or transport across the blood-brain barrier, e.g., an antibody to the transferrin receptor. In cases, the antisense oligonucleotide is linked with a viral vector, e.g., to render the antisense compound more effective or increase transport across the blood-brain barrier. In cases, osmotic blood brain barrier disruption is assisted by infusion of sugars, e.g.,, meso erythritol, xylitol, D(+) galactose, D(+) lactose, D(+) xylose, dulcitol, myo-inositol, L(-) fructose, D(-) mannitol, D(+) glucose, D(+) arabinose, D(-) arabinose, cellobiose, D(+) maltose, D(+) raffinose, L(+) rhamnose, D(+) melibiose, D(-) ribose, adonitol, D(+) arabitol, L(-) arabitol, D(+) fucose, L(-) fucose, D(-) lyxose, L(+) lyxose, and L(-) lyxose, or amino acids, e.g., glutamine, lysine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glycine, histidine, leucine, methionine, phenylalanine, proline, serine, threonine, tyrosine, valine, and taurine. Methods and materials for enhancing blood brain barrier penetration are described, e.g., in U.S. Pat. No. 4,866,042 , "Method for the delivery of genetic material across the blood brain barrier," U.S. Pat. No. 6,294,520 , "Material for passage through the blood-brain barrier," and U.S. Pat. No. 6,936,589 , "Parenteral delivery systems," each incorporated herein by reference.

In cases, the antisense oligonucleotides of the disclosure are chemically linked to one or more moieties or conjugates, e.g., a targeting moiety or other conjugate that enhances the activity or cellular uptake of the oligonucleotide. Such moieties include, but are not limited to, a lipid moiety, e.g., as a cholesterol moiety, a cholesteryl moiety, an aliphatic chain, e.g., dodecandiol or undecyl residues, a polyamine or a polyethylene glycol chain, or adamantane acetic acid. Oligonucleotides comprising lipophilic moieties, and preparation methods have been described in the published literature. In cases, the antisense oligonucleotide is conjugated with a moiety including, but not limited to, an abasic nucleotide, a polyether, a polyamine, a polyamide, a peptides, a carbohydrate, e.g., N-acetylgalactosamine (GalNAc), N-Ac-Glucosamine (GluNAc), or mannose (e.g., mannose-6-phosphate), a lipid, or a polyhydrocarbon compound. Conjugates can be linked to one or more of any nucleotides comprising the antisense oligonucleotide at any of several positions on the sugar, base or phosphate group, as understood in the art and described in the literature, e.g., using a linker. Linkers can include a bivalent or trivalent branched linker. In cases, the conjugate is attached to the 3' end of the antisense oligonucleotide. Methods of preparing oligonucleotide conjugates are described, e.g., in U.S. Pat. No. 8,450,467 , "Carbohydrate conjugates as delivery agents for oligonucleotides,".

Treatment of Subjects

Any of the compositions provided herein may be administered to an individual. "Individual" may be used interchangeably with "subject" or "patient." An individual may be a mammal, for example a human or animal such as a non-human primate, a rodent, a rabbit, a rat, a mouse, a horse, a donkey, a goat, a cat, a dog, a cow, a pig, or a sheep. In cases, the individual is a human. In cases, the individual is a fetus, an embryo, or a child. In other cases, the individual may be another eukaryotic organism, such as a plant. In some cases, the compositions provided herein are administered to a cell ex vivo.

In some cases, the compositions provided herein are administered to an individual as a method of treating a disease or disorder. In some cases, the individual has a genetic disease, such as any of the diseases described herein. In some cases, the individual is at risk of having the disease, such as any of the diseases described herein. In some cases, the individual is at increased risk of having a disease or disorder caused by insufficient amount of a protein or insufficient activity of a protein. If an individual is "at an increased risk" of having a disease or disorder caused insufficient amount of a protein or insufficient activity of a protein, the method involves preventative or prophylactic treatment. For example, an individual may be at an increased risk of having such a disease or disorder because of family history of the disease. Typically, individuals at an increased risk of having such a disease or disorder benefit from prophylactic treatment (e.g., by preventing or delaying the onset or progression of the disease or disorder).

Suitable routes for administration of ASOs of the present disclosure may vary depending on cell type to which delivery of the ASOs is desired. The eye is the most significantly affected tissue in RP13 and RP18. An ASO of the present disclosure may therefore be administered to a subject by intravitreal injection, by subretinal injection, or by topical application to the eye. In cases, an ASO of the present disclosure administered to a subject via an implant, e.g., an encapsulated drug implanted in the eye. In cases, RPE cells treated ex vivo with an ASO of the present disclosure are implanted in the eye, e.g., in encapsulated form. In cases, therapy is administered in conjunction with existing treatments for RP, e.g., oral acetazolamide, calcium channel blockers, lutein or zeaxanthin, oral valproic acid, or an immunosuppressive agent. In cases, ASOs are administered parenterally. In cases, ASOs of the present disclosure are administered to a subject orally, by intraperitoneal injection, intramuscular injection, subcutaneous injection, or intravenous injection. In cases, a fetus is treated in utero, e.g., by administering the ASO composition to the fetus directly or indirectly (e.g., via the mother).

In cases, subjects treated using the methods and compositions are evaluated for improvement in condition using any methods known and described in the art.

Methods of identifying additional ASOs that enhance splicing

Also within the scope of the present disclosure are methods for identifying (determining) additional ASOs that enhance splicing of a PRPF3 or PRPF8 RIC pre-mRNA, specifically at the target intron. ASOs that specifically hybridize to different nucleotides within the target region of the pre-mRNA may be screened to identify (determine) ASOs that improve the rate and/or extent of splicing of the target intron. In some cases, the ASO may block or interfere with the binding site(s) of a splicing repressor(s)/silencer. Any method known in the art may be used to identify (determine) an ASO that when hybridized to the target region of the intron results in the desired effect (e.g., enhanced splicing, protein or functional RNA production). These methods also can be used for identifying ASOs that enhance splicing of the retained intron by binding to a targeted region in an exon flanking the retained intron, or in a non-retained intron. An example of a method that may be used is provided below.

A round of screening, referred to as an ASO "walk" may be performed using ASOs that have been designed to hybridize to a target region of a pre-mRNA. For example, the ASOs used in the ASO walk can be tiled every 5 nucleotides from approximately 100 nucleotides upstream of the 5' splice site of the retained intron (e.g., a portion of sequence of the exon located upstream of the target/retained intron) to approximately 100 nucleotides downstream of the 5' splice site of the target/retained intron and/or from approximately 100 nucleotides upstream of the 3' splice site of the retained intron to approximately 100 nucleotides downstream of the 3' splice site of the target/retained intron (e.g., a portion of sequence of the exon located downstream of the target/retained intron). For example, a first ASO of 15 nucleotides in length may be designed to specifically hybridize to nucleotides +6 to +20 relative to the 5' splice site of the target/retained intron. A second ASO is designed to specifically hybridize to nucleotides +11 to +25 relative to the 5' splice site of the target/retained intron. ASOs are designed as such spanning the target region of the pre-mRNA. In cases, the ASOs can be tiled more closely, e.g., every 1, 2, 3, or 4 nucleotides. Further, the ASOs can be tiled from 100 nucleotides downstream of the 5' splice site, to 100 nucleotides upstream of the 3' splice site.

One or more ASOs, or a control ASO (an ASO with a scrambled sequence, sequence that is not expected to hybridize to the target region) are delivered, for example by transfection, into a disease-relevant cell line that expresses the target pre-mRNA (e.g., the RIC pre-mRNA described elsewhere herein). The splicing-inducing effects of each of the ASOs may be assessed by any method known in the art, for example by reverse transcriptase (RT)-PCR using primers that span the splice junction, as described herein (see "Identification of intron-retention events"). A reduction or absence of the RT-PCR product produced using the primers spanning the splice junction in ASO-treated cells as compared to in control ASO-treated cells indicates that splicing of the target intron has been enhanced. In some cases, the splicing efficiency, the ratio of spliced to unspliced pre-mRNA, the rate of splicing, or the extent of splicing may be improved using the ASOs described herein. The amount of protein or functional RNA that is encoded by the target pre-mRNA can also be assessed to determine whether each ASO achieved the desired effect (e.g., enhanced protein production). Any method known in the art for assessing and/or quantifying protein production, such as Western blotting, flow cytometry, immunofluorescence microscopy, and ELISA, can be used.

A second round of screening, referred to as an ASO "micro-walk" may be performed using ASOs that have been designed to hybridize to a target region of a pre-mRNA. The ASOs used in the ASO micro-walk are tiled every 1 nucleotide to further refine the nucleotide acid sequence of the pre-mRNA that when hybridized with an ASO results in enhanced splicing.

Regions defined by ASOs that promote splicing of the target intron are explored in greater detail by means of an ASO "micro-walk", involving ASOs spaced in 1-nt steps, as well as longer ASOs, typically 18-25 nt.

As described for the ASO walk above, the ASO micro-walk is performed by delivering one or more ASOs, or a control ASO (an ASO with a scrambled sequence, sequence that is not expected to hybridize to the target region), for example by transfection, into a disease-relevant cell line that expresses the target pre-mRNA. The splicing-inducing effects of each of the ASOs may be assessed by any method known in the art, for example by reverse transcriptase (RT)-PCR using primers that span the splice junction, as described herein (see "Identification of intron-retention events"). A reduction or absence of the RT-PCR product produced using the primers spanning the splice junction in ASO-treated cells as compared to in control ASO-treated cells indicates that splicing of the target intron has been enhanced. In some cases, the splicing efficiency, the ratio of spliced to unspliced pre-mRNA, the rate of splicing, or the extent of splicing may be improved using the ASOs described herein. The amount of protein or functional RNA that is encoded by the target pre-mRNA can also be assessed to determine whether each ASO achieved the desired effect (e.g., enhanced protein production). Any method known in the art for assessing and/or quantifying protein production, such as Western blotting, flow cytometry, immunofluorescence microscopy, and ELISA, can be used.

ASOs that when hybridized to a region of a pre-mRNA result in enhanced splicing and increased protein production may be tested in vivo using animal models, for example transgenic mouse models in which the full-length human gene has been knocked-in or in humanized mouse models of disease. Suitable routes for administration of ASOs may vary depending on the disease and/or the cell types to which delivery of the ASOs is desired. ASOs may be administered, for example, by intravitreal injection, by subretinal injection, by topical application to the eye, or by an encapsulated drug implanted in the eye. Following administration, the cells, tissues, and/or organs of the model animals may be assessed to determine the effect of the ASO treatment by for example evaluating splicing (efficiency, rate, extent) and protein production by methods known in the art and described herein. The animal models may also be any phenotypic or behavioral indication of the disease or disease severity.

EXAMPLES

The present disclosure will be more specifically illustrated by the following Examples.

Example 1: Identification of intron retention events in PRPF3 transcripts by RNAseq using next generation sequencing

Whole transcriptome shotgun sequencing was carried out using next generation sequencing to reveal a snapshot of transcripts produced by the PRPF3 gene to identify intron-retention events. For this purpose, polyA+ RNA from nuclear and cytoplasmic fractions of ARPE-19 (retinal epithelial) cells was isolated and cDNA libraries constructed using Illumina's TruSeq Stranded mRNA library Prep Kit. The libraries were pair-end sequenced resulting in 100-nucleotide reads that were mapped to the human genome (Feb. 2009, GRCh37/hg19 assembly). The sequencing results for PRPF3 are shown in Figure 3. Briefly, Figure 3 shows the mapped reads visualized using the UCSC genome browser (operated by the UCSC Genome Informatics Group (Center for Biomolecular Science & Engineering, University of California, Santa Cruz, 1156 High Street, Santa Cruz, CA 95064) and described by, e.g., Rosenbloom, et al., 2015, "The UCSC Genome Browser database: 2015 update," Nucleic Acids Research 43, Database Issue, doi: 10.1093/nar/gku1177) and the coverage and number of reads can be inferred by the peak signals. The height of the peaks indicates the level of expression given by the density of the reads in a particular region. A schematic representation of PRPF3 (drawn to scale) is provided by the UCSC genome browser (below the read signals) so that peaks can be matched to PRPF3 exonic and intronic regions. Based on this display, we identified 2 introns in PRPF3 (12 and 13, indicated by arrows, corresponding to NM_004698: intron 12, and NM_004698; intron 13, respectively) and 1 intron in PRPF8 (31, indicated by the arrow, corresponding to NM_006445, intron 31) (Figure 7) that have high read density in the nuclear fraction of ARPE-19 cells, but have very low to no reads in the cytoplasmic fraction of these cells (as shown for intron 12 in the bottom diagram of Figure 3, 13 in the bottom diagram of Figure 5, and for introns 31 in the bottom diagram of Figure 5). This indicates that these introns are retained and that the intron-12 and intron-13, and, intron-31 containing transcripts remain in the nucleus, and suggests that these retained PRPF3 and PRPF8 RIC pre-mRNAs, respectively are non-productive, as they are not exported out to the cytoplasm.

Example 2: Design of ASO-walk targeting a retained intron

An ASO walk was designed to target intron 12 of PRPF3 using the method described herein (FIG. 4). A region immediately downstream of the intron 12 5' splice site spanning nucleotides +6 to +498 and a region immediately upstream of intron 12 3' splice site spanning nucleotides -16 to -496 of the intron were targeted with 2'-O-Me RNA, PS backbone, 18-mer ASOs shifted by 5-nucleotide intervals (with the exception of ASO P3-IVS12+28).

An ASO walk was designed to target intron 13 of PRPF3 using the method described herein (FIG. 6). A region immediately downstream of the intron 13 5' splice site spanning nucleotides +6 to +146 and a region immediately upstream of intron 13 3' splice site spanning nucleotides -16 to -146 of the intron were targeted with 2'-O-Me RNA, PS backbone, 18-mer ASOs shifted by 5-nucleotide intervals (with the exception of ASOs P3-IVS13+15, P3-IVS13+31, and P3-IVS13-47).

An ASO walk was designed to target intron 31 of PRPF8 using the method described herein (FIG. 8). A region immediately downstream of the intron 31 5' splice site spanning nucleotides +6 to +156 and a region immediately upstream of intron 31 3' splice site spanning nucleotides -16 to -156 were targeted with 2'-O-Me RNA, PS backbone, 18-mer ASOs shifted by 5-nucleotide intervals.

Table 1 lists exemplary ASOs that were designed and their target sequences. Table 1

Gene SEQ ID NO.	Pre-mRNA SEQ ID NO.	ASOs	Retained Intron	Target Sequence SEQ ID NO.
PRPF3 SEQ ID NO. 1	PRPF3:NM_004698 SEQ ID NO. 3	5-239	12	447
		240-323	13	446
PRPF8 SEQ ID NO. 2	PRPF8:NM_006445 SEQ ID NO. 4	324-445	31	448

Example 3: Improved splicing efficiency via ASO-targeting of PRPF3 intron 12 increases transcript levels

To determine whether an increase in target gene intron splicing efficiency could be achieved with ASOs, the method described herein was used. ARPE-19 cells, a human retinal epithelium cell line (American Type Culture Collection (ATCC), USA) were mock-transfected, or transfected with the targeting ASOs described in Table 1. Cells were transfected using Lipofectamine RNAiMax transfection reagent (Thermo Fisher) according to vendor's specifications. Briefly, ASOs were plated in 96-well tissue culture plates and combined with RNAiMax diluted in Opti-MEM. Cells were detached using trypsin and resuspended in full medium, and approximately 25,000 cells were added the ASO-transfection mixture. Transfection experiments were carried out in triplicate plate replicates. Final ASO concentration was 80 nM. Media was changed 6h post-transfection, and cells harvested at 24h, using the Cells-to-Ct lysis reagent, supplemented with DNAse (Thermo Fisher), according to vendor's specifications. cDNA was generated with Cells-to-Ct RT reagents (Thermo Fisher) according to vendor's specifications. To quantify the amount of splicing at the intron of interest, quantitative PCR was carried out using Taqman assays with probes spanning the corresponding exon-exon junction (Thermo Fisher). Taqman assays were carried out according to vendor's specifications, on a QuantStudio 7 Flex Real-Time PCR system (Thermo Fisher). Target gene assay values were normalized to RPL32 (deltaCt) and plate-matched mock transfected samples (delta-delta Ct), generating fold-change over mock quantitation (2^-(delta-deltaCt). Average fold-change over mock of the three plate replicates was plotted (FIG. 10). Several ASOs were identified that increased the target gene expression, as shown in FIG. 10, implying an increase in splicing at that target intron. Together with whole transcriptome data confirming retention of the target intron (FIG. 9), these results confirm that ASOs can improve the splicing efficiency of a rate limiting intron.

Example 4: Improved splicing efficiency via ASO-targeting of PRPF3 intron 13 increases transcript levels

To determine whether an increase in target gene intron splicing efficiency could be achieved with ASOs, the method described herein was used. ARPE-19 cells, a human retinal epithelium cell line (American Type Culture Collection (ATCC), USA) were mock-transfected, or transfected with the targeting ASOs described in Table 1. Cells were transfected using Lipofectamine RNAiMax transfection reagent (Thermo Fisher) according to vendor's specifications. Briefly, ASOs were plated in 96-well tissue culture plates and combined with RNAiMax diluted in Opti-MEM. Cells were detached using trypsin and resuspended in full medium, and approximately 25,000 cells were added the ASO-transfection mixture. Transfection experiments were carried out in triplicate plate replicates. Final ASO concentration was 80 nM. Media was changed 6h post-transfection, and cells harvested at 24h, using the Cells-to-Ct lysis reagent, supplemented with DNAse (Thermo Fisher), according to vendor's specifications. cDNA was generated with Cells-to-Ct RT reagents (Thermo Fisher) according to vendor's specifications. To quantify the amount of splicing at the intron of interest, quantitative PCR was carried out using Taqman assays with probes spanning the corresponding exon-exon junction (Thermo Fisher). Taqman assays were carried out according to vendor's specifications, on a QuantStudio 7 Flex Real-Time PCR system (Thermo Fisher). Target gene assay values were normalized to RPL32 (deltaCt) and plate-matched mock transfected samples (delta-delta Ct), generating fold-change over mock quantitation (2^-(delta-deltaCt). Average fold-change over mock of the three plate replicates was plotted (FIG. 10, FIG. 12). Several ASOs were identified that increased the target gene expression, as shown in FIG. 12, implying an increase in splicing at that target intron. Together with whole transcriptome data confirming retention of the target intron (FIG. 11), these results confirm that ASOs can improve the splicing efficiency of a rate limiting intron.

Example 5: Improved splicing efficiency via ASO-targeting of PRPF8 intron 31 increases transcript levels

To determine whether an increase in target gene intron splicing efficiency could be achieved with ASOs, the method described herein was used. ARPE-19 cells, a human retinal epithelium cell line (American Type Culture Collection (ATCC), USA) were mock-transfected, or transfected with the targeting ASOs described in Table 1. Cells were transfected using Lipofectamine RNAiMax transfection reagent (Thermo Fisher) according to vendor's specifications. Briefly, ASOs were plated in 96-well tissue culture plates and combined with RNAiMax diluted in Opti-MEM. Cells were detached using trypsin and resuspended in full medium, and approximately 25,000 cells were added the ASO-transfection mixture. Transfection experiments were carried out in triplicate plate replicates. Final ASO concentration was 80 nM. Media was changed 6h post-transfection, and cells harvested at 24h, using the Cells-to-Ct lysis reagent, supplemented with DNAse (Thermo Fisher), according to vendor's specifications. cDNA was generated with Cells-to-Ct RT reagents (Thermo Fisher) according to vendor's specifications. To quantify the amount of splicing at the intron of interest, quantitative PCR was carried out using Taqman assays with probes spanning the corresponding exon-exon junction (Thermo Fisher). Taqman assays were carried out according to vendor's specifications, on a QuantStudio 7 Flex Real-Time PCR system (Thermo Fisher). Target gene assay values were normalized to RPL32 (deltaCt) and plate-matched mock transfected samples (delta-delta Ct), generating fold-change over mock quantitation (2^-(delta-deltaCt). Average fold-change over mock of the three plate replicates is plotted (FIG. 14). Several ASOs were identified that increased the target gene expression, as shown in FIG. 14, implying an increase in splicing at that target intron. Together with whole transcriptome data confirming retention of the target intron (FIG. 13), these results confirm that ASOs can improve the splicing efficiency of a rate limiting intron.

SEQUENCE LISTING

• <110> COLD SPRING HARBOR LABORATORY STOKE THERAPEUTICS, INC.
• <120> COMPOSITIONS AND METHODS FOR TREATMENT OF RETINITIS PIGMENTOSA 18 AND RETINITIS PIGMENTOSA 13
• <130> 47991-709.601
• <140> <141>
• <150> 62/267,261 <151> 2015-12-14
• <160> 448
• <170> PatentIn version 3.5
• <210> 1 <211> 31777 <212> DNA <213> Homo sapiens
• <400> 1
• <210> 2 <211> 34254 <212> DNA <213> Homo sapiens
• <400> 2
• <210> 3 <211> 31777 <212> RNA <213> Homo sapiens
• <400> 3
• <210> 4 <211> 34254 <212> RNA <213> Homo sapiens
• <400> 4
• <210> 5 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 5 gcguuggccu cuucaugc   18
• <210> 6 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 6 gggcagcguu ggccucuu   18
• <210> 7 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 7 uuuucgggca gcguuggc   18
• <210> 8 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 8 gugaguuuuc gggcagcg   18
• <210> 9 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 9 cugcugugag uuuucggg   18
• <210> 10 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 10 cuguucugcu gugaguuu   18
• <210> 11 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 11 uuucucuguu cugcugug   18
• <210> 12 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 12 ugaccuuucu cuguucug   18
• <210> 13 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 13 uuucuugacc uuucucug   18
• <210> 14 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 14 uuaauuuucu ugaccuuu   18
• <210> 15 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 15 gcuuuuuaau uuucuuga   18
• <210> 16 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 16 uuuaagcuuu uuaauuuu   18
• <210> 17 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 17 ucuucuuuaa gcuuuuua   18
• <210> 18 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 18 aaaugucuuc uuuaagcu   18
• <210> 19 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 19 cugugaaaug ucuucuuu    18
• <210> 20 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 20 acccccugug aaaugucu    18
• <210> 21 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 21 uguguacccc cugugaaa    18
• <210> 22 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 22 agauaugugu acccccug    18
• <210> 23 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 23 uauacagaua uguguacc    18
• <210> 24 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 24 uuuggcccag uauggaca    18
• <210> 25 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 25 ggaaguuugg cccaguau    18
• <210> 26 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 26 gggaaguuug gcccagua    18
• <210> 27 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 27 uuuuaguaau ucuaaggg    18
• <210> 28 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 28 aaauguuuua guaauucu    18
• <210> 29 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 29 uuggaaaaug uuuuagua    18
• <210> 30 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 30 agcacuugga aaauguuu    18
• <210> 31 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 31 ccucaagcac uuggaaaa    18
• <210> 32 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 32 uucugccuca agcacuug    18
• <210> 33 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 33 aaugauucug ccucaagc    18
• <210> 34 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 34 gccacaauga uucugccu    18
• <210> 35 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 35 uuuaggccac aaugauuc    18
• <210> 36 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 36 augcuuuuag gccacaau    18
• <210> 37 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 37 uagguaugcu uuuaggcc    18
• <210> 38 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 38 gguguuaggu augcuuuu    18
• <210> 39 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 39 gaacuggugu uagguaug    18
• <210> 40 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 40 aguaggaacu gguguuag    18
• <210> 41 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 41 aagagaguag gaacuggu    18
• <210> 42 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 42 auuaaaagag aguaggaa    18
• <210> 43 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 43 gggucauuaa aagagagu    18
• <210> 44 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 44 cacuaggguc auuaaaag    18
• <210> 45 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 45 auccacacua gggucauu    18
• <210> 46 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 46 ucuugaucca cacuaggg    18
• <210> 47 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 47 cuagcucuug auccacac    18
• <210> 48 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 48 auuuacuagc ucuugauc    18
• <210> 49 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 49 acaagauuua cuagcucu    18
• <210> 50 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 50 auuuuacaag auuuacua    18
• <210> 51 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 51 ucgcuauuuu acaagauu    18
• <210> 52 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 52 aacucucgcu auuuuaca    18
• <210> 53 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 53 ucauuaacuc ucgcuauu    18
• <210> 54 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 54 auaagucauu aacucucg    18
• <210> 55 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 55 uaaacauaag ucauuaac    18
• <210> 56 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 56 aaccauaaac auaaguca    18
• <210> 57 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 57 uggguaacca uaaacaua    18
• <210> 58 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 58 agaacugggu aaccauaa    18
• <210> 59 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 59 agggaagaac uggguaac    18
• <210> 60 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 60 uugagaggga agaacugg    18
• <210> 61 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 61 aagacuugag agggaaga    18
• <210> 62 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 62 aaaagaagac uugagagg    18
• <210> 63 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 63 aaaaaaaaag aagacuug    18
• <210> 64 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 64 gguaaaaaaa aaaagaag    18
• <210> 65 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 65 auucugguaa aaaaaaaa    18
• <210> 66 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 66 cuaauauucu gguaaaaa    18
• <210> 67 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 67 cagaacuaau auucuggu    18
• <210> 68 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 68 uuguucagaa cuaauauu    18
• <210> 69 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 69 uugacuuguu cagaacua    18
• <210> 70 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 70 guauauugac uuguucag    18
• <210> 71 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 71 aacaaguaua uugacuug    18
• <210> 72 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 72 gccugaacaa guauauug    18
• <210> 73 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 73 ucuuggccug aacaagua    18
• <210> 74 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 74 ucacaucuug gccugaac    18
• <210> 75 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 75 uuaguucaca ucuuggcc    18
• <210> 76 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 76 aaucuuuagu ucacaucu    18
• <210> 77 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 77 cauacaaucu uuaguuca    18
• <210> 78 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 78 aaggacauac aaucuuua    18
• <210> 79 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 79 ucucaaagga cauacaau    18
• <210> 80 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 80 auaguucuca aaggacau    18
• <210> 81 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 81 auuuuauagu ucucaaag    18
• <210> 82 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 82 augauauuuu auaguucu    18
• <210> 83 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 83 auaggaugau auuuuaua    18
• <210> 84 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 84 aagaaauagg augauauu    18
• <210> 85 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 85 aaaaaaagaa auaggaug    18
• <210> 86 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 86 ugaaaaaaaa aagaaaua    18
• <210> 87 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 87 aaagaugaaa aaaaaaag    18
• <210> 88 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 88 aaaaaaaaga ugaaaaaa    18
• <210> 89 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 89 uuaaaaaaaa aaagauga    18
• <210> 90 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 90 accauuuaaa aaaaaaaa    18
• <210> 91 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 91 cucagaccau uuaaaaaa    18
• <210> 92 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 92 gcaaacucag accauuua    18
• <210> 93 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 93 uggaagcaaa cucagacc    18
• <210> 94 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 94 gauguuggaa gcaaacuc    18
• <210> 95 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 95 ccauggaugu uggaagca    18
• <210> 96 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 96 ugcuuccaug gauguugg    18
• <210> 97 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 97 uguaaugcuu ccauggau    18
• <210> 98 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 98 aaauuuguaa ugcuucca    18
• <210> 99 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 99 aaagaaaauu uguaaugc    18
• <210> 100 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 100 ggaggaaaga aaauuugu    18
• <210> 101 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 101 acuacggagg aaagaaaa    18
• <210> 102 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 102 auaugacuac ggaggaaa    18
• <210> 103 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 103 uaaggauaug acuacgga    18
• <210> 104 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 104 caggguaagg auaugacu    18
• <210> 105 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 105 uacaucaggg uaaggaua    18
• <210> 106 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 106 agcaauacau caggguaa    18
• <210> 107 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 107 aacacagcaa uacaucag    18
• <210> 108 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 108 gaugaaacac agcaauac    18
• <210> 109 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 109 gugaggauga aacacagc    18
• <210> 110 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 110 uuggagugag gaugaaac    18
• <210> 111 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 111 gcauuuugga gugaggau    18
• <210> 112 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 112 aaaaugcauu uuggagug    18
• <210> 113 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 113 cauauaaaau gcauuuug    18
• <210> 114 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 114 uacaacauau aaaaugca    18
• <210> 115 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 115 auauuuacaa cauauaaa    18
• <210> 116 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 116 gaaaaauauu uacaacau    18
• <210> 117 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 117 agguagaaaa auauuuac    18
• <210> 118 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 118 cacaaaggua gaaaaaua    18
• <210> 119 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 119 aucaacacaa agguagaa    18
• <210> 120 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 120 auuaaaucaa cacaaagg    18
• <210> 121 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 121 aaaacauuaa aucaacac    18
• <210> 122 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 122 aaaaauuagc cgggcgug    18
• <210> 123 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 123 aauacaaaaa uuagccgg    18
• <210> 124 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 124 cuaaaaauac aaaaauua    18
• <210> 125 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 125 cucuacuaaa aauacaaa    18
• <210> 126 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 126 cccaucucua cuaaaaau    18
• <210> 127 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 127 gaaaccccau cucuacua    18
• <210> 128 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 128 auggugaaac cccaucuc    18
• <210> 129 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 129 ccaacauggu gaaacccc    18
• <210> 130 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 130 ccuggccaac auggugaa    18
• <210> 131 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 131 accagccugg ccaacaug   18
• <210> 132 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 132 uuaagaccag ccuggcca    18
• <210> 133 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 133 ggaguuuaag accagccu    18
• <210> 134 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 134 ggucaggagu uuaagacc    18
• <210> 135 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 135 cacgagguca ggaguuua    18
• <210> 136 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 136 cagaucacga ggucagga    18
• <210> 137 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 137 gugggcagau cacgaggu    18
• <210> 138 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 138 ccaaaguggg cagaucac    18
• <210> 139 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 139 ggaggccaaa gugggcag    18
• <210> 140 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 140 cuuugggagg ccaaagug    18
• <210> 141 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 141 cagcacuuug ggaggcca    18
• <210> 142 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 142 aaucccagca cuuuggga    18
• <210> 143 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 143 ccuguaaucc cagcacuu    18
• <210> 144 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 144 ucaugccugu aaucccag    18
• <210> 145 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 145 guggcucaug ccuguaau    18
• <210> 146 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 146 gugcgguggc ucaugccu    18
• <210> 147 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 147 gcugggugcg guggcuca    18
• <210> 148 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 148 acuuggcugg gugcggug    18
• <210> 149 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 149 ggauuacuug gcugggug    18
• <210> 150 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 150 auauaggauu acuuggcu    18
• <210> 151 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 151 uuauaauaua ggauuacu    18
• <210> 152 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 152 gacucuuaua auauagga    18
• <210> 153 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 153 ccuuagacuc uuauaaua    18
• <210> 154 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 154 uagacccuua gacucuua    18
• <210> 155 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 155 uccucuagac ccuuagac    18
• <210> 156 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 156 uuuuguccuc uagacccu    18
• <210> 157 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 157 agacuuuuug uccucuag    18
• <210> 158 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 158 ccuacagacu uuuugucc    18
• <210> 159 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 159 aaagaccuac agacuuuu    18
• <210> 160 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 160 aauguaaaga ccuacaga    18
• <210> 161 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 161 uugacaaugu aaagaccu    18
• <210> 162 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 162 uguucuugac aauguaaa    18
• <210> 163 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 163 cucauuguuc uugacaau    18
• <210> 164 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 164 acaaucucau uguucuug    18
• <210> 165 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 165 uacuuacaau cucauugu    18
• <210> 166 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 166 aaaaauacuu acaaucuc    18
• <210> 167 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 167 cauccaaaaa uacuuaca    18
• <210> 168 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 168 acuaucaucc aaaaauac    18
• <210> 169 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 169 uauuuacuau cauccaaa    18
• <210> 170 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 170 agagguauuu acuaucau    18
• <210> 171 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 171 cagggagagg uauuuacu    18
• <210> 172 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 172 agagucaggg agagguau    18
• <210> 173 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 173 cucuaagagu cagggaga    18
• <210> 174 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 174 guuuacucua agagucag    18
• <210> 175 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 175 ccaaaguuua cucuaaga    18
• <210> 176 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 176 acuaaccaaa guuuacuc    18
• <210> 177 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 177 acauuacuaa ccaaaguu    18
• <210> 178 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 178 ccauuacauu acuaacca    18
• <210> 179 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 179 auuaaccauu acauuacu    18
• <210> 180 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 180 uuuacauuaa ccauuaca    18
• <210> 181 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 181 agcacuuuac auuaacca    18
• <210> 182 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 182 agucuagcac uuuacauu    18
• <210> 183 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 183 uucaaagucu agcacuuu    18
• <210> 184 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 184 auuucuucaa agucuagc    18
• <210> 185 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 185 cuuacauuuc uucaaagu    18
• <210> 186 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 186 acacucuuac auuucuuc    18
• <210> 187 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 187 uuuccacacu cuuacauu    18
• <210> 188 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 188 aaauauuucc acacucuu    18
• <210> 189 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 189 ucuagaaaua uuuccaca   18
• <210> 190 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 190 augagucuag aaauauuu    18
• <210> 191 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 191 aguugaugag ucuagaaa    18
• <210> 192 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 192 gguagaguug augagucu   18
• <210> 193 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 193 uaaaagguag aguugaug   18
• <210> 194 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 194 augcuuaaaa gguagagu   18
• <210> 195 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 195 gaugaaugcu uaaaaggu   18
• <210> 196 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 196 aaauagauga augcuuaa   18
• <210> 197 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 197 uaaacaaaua gaugaaug   18
• <210> 198 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 198 uggaguaaac aaauagau   18
• <210> 199 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 199 gccucuggag uaaacaaa   18
• <210> 200 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 200 caaaggccuc uggaguaa   18
• <210> 201 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 201 auaaacaaag gccucugg   18
• <210> 202 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 202 ucucuauaaa caaaggcc   18
• <210> 203 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 203 uuuccucucu auaaacaa   18
• <210> 204 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 204 aaugguuucc ucucuaua   18
• <210> 205 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 205 uccaaaaugg uuuccucu   18
• <210> 206 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 206 augaauccaa aaugguuu   18
• <210> 207 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 207 aaaagaugaa uccaaaau   18
• <210> 208 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 208 aaguaaaaag augaaucc   18
• <210> 209 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 209 guggcaagua aaaagaug   18
• <210> 210 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 210 auggaguggc aaguaaaa   18
• <210> 211 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 211 ccugaaugga guggcaag   18
• <210> 212 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 212 agcugccuga auggagug   18
• <210> 213 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 213 ucagcagcug ccugaaug   18
• <210> 214 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 214 uagcaucagc agcugccu   18
• <210> 215 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 215 cauuuuagca ucagcagc   18
• <210> 216 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 216 ucuuccauuu uagcauca   18
• <210> 217 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 217 uuaugucuuc cauuuuag   18
• <210> 218 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 218 uuuaguuaug ucuuccau   18
• <210> 219 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 219 guugcucaaa uuucgaac   18
• <210> 220 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 220 gcuggguugc ucaaauuu   18
• <210> 221 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 221 ucuuggcugg guugcuca   18
• <210> 222 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 222 gaacuucuug gcuggguu   18
• <210> 223 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 223 aucuugaacu ucuuggcu   18
• <210> 224 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 224 cuucaaucuu gaacuucu   18
• <210> 225 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 225 auuggcuuca aucuugaa   18
• <210> 226 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 226 ccagcauugg cuucaauc   18
• <210> 227 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 227 guugcccagc auuggcuu   18
• <210> 228 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 228 guacaguugc ccagcauu   18
• <210> 229 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 229 gucagguaca guugccca   18
• <210> 230 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 230 ccccugucag guacaguu   18
• <210> 231 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 231 caccaccccu gucaggua   18
• <210> 232 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 232 aguaccacca ccccuguc   18
• <210> 233 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 233 ugugcaguac caccaccc   18
• <210> 234 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 234 auccuugugc aguaccac   18
• <210> 235 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 235 uugacauccu ugugcagu   18
• <210> 236 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 236 ccacguugac auccuugu   18
• <210> 237 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 237 uacuaccacg uugacauc   18
• <210> 238 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 238 uccacuacua ccacguug   18
• <210> 239 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 239 ccccuuccac uacuacca   18
• <210> 240 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 240 ggguugcuca aauuucga   18
• <210> 241 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 241 uggcuggguu gcucaaau   18
• <210> 242 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 242 cuucuuggcu ggguugcu   18
• <210> 243 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 243 uugaacuucu uggcuggg   18
• <210> 244 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 244 caaucuugaa cuucuugg   18
• <210> 245 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 245 ggcuucaauc uugaacuu   18
• <210> 246 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 246 gcauuggcuu caaucuug   18
• <210> 247 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 247 gcccagcauu ggcuucaa   18
• <210> 248 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 248 caguugccca gcauuggc   18
• <210> 249 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 249 agguacaguu gcccagca   18
• <210> 250 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 250 cugucaggua caguugcc   18
• <210> 251 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 251 caccccuguc agguacag   18
• <210> 252 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 252 accaccaccc cugucagg   18
• <210> 253 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 253 gcaguaccac caccccug   18
• <210> 254 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 254 cuugugcagu accaccac   18
• <210> 255 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 255 acauccuugu gcaguacc   18
• <210> 256 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 256 cguugacauc cuugugca   18
• <210> 257 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 257 uaccacguug acauccuu   18
• <210> 258 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 258 acuacuacca cguugaca   18
• <210> 259 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 259 cuuccacuac uaccacgu   18
• <210> 260 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 260 ucccucaagu uuuucaga   18
• <210> 261 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 261 cagucucccu caaguuuu   18
• <210> 262 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 262 gggacagucu cccucaag   18
• <210> 263 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 263 agccuagggu ugucuggg   18
• <210> 264 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 264 cucuaagccu aggguugu   18
• <210> 265 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 265 aaucacucua agccuagg   18
• <210> 266 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 266 augcuaauca cucuaagc   18
• <210> 267 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 267 ccacaaugcu aaucacuc   18
• <210> 268 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 268 ucuccccaca augcuaau   18
• <210> 269 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 269 uccuuucucc ccacaaug   18
• <210> 270 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 270 uuuucuccuu ucucccca   18
• <210> 271 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 271 gaucuuuuuc uccuuucu   18
• <210> 272 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 272 aauacgaucu uuuucucc   18
• <210> 273 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 273 acuaaaauac gaucuuuu   18
• <210> 274 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 274 auggcacuaa aauacgau   18
• <210> 275 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 275 cagguauggc acuaaaau   18
• <210> 276 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 276 uauaucaggu auggcacu   18
• <210> 277 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 277 cauauuauau cagguaug   18
• <210> 278 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 278 ccuagcauau uauaucag   18
• <210> 279 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 279 agagaccuag cauauuau   18
• <210> 280 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 280 gaagcagaga ccuagcau   18
• <210> 281 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 281 acacagaagc agagaccu   18
• <210> 282 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 282 aaaaaacaca gaagcaga   18
• <210> 283 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 283 acuccaaaaa acacagaa   18
• <210> 284 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 284 cuucuacucc aaaaaaca   18
• <210> 285 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 285 agggccuucu acuccaaa   18
• <210> 286 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 286 aucuuagggc cuucuacu   18
• <210> 287 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 287 agaccuagca uauuauau   18
• <210> 288 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 288 agcagagacc uagcauau   18
• <210> 289 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 289 acagaagcag agaccuag   18
• <210> 290 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 290 aaaacacaga agcagaga   18
• <210> 291 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 291 uccaaaaaac acagaagc   18
• <210> 292 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 292 ucuacuccaa aaaacaca   18
• <210> 293 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 293 ggccuucuac uccaaaaa   18
• <210> 294 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 294 cuuagggccu ucuacucc   18
• <210> 295 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 295 cacaucuuag ggccuucu   18
• <210> 296 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 296 ggaaccacau cuuagggc   18
• <210> 297 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 297 ucucaggaac cacaucuu   18
• <210> 298 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 298 agcaaucuca ggaaccac   18
• <210> 299 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 299 guugaagcaa ucucagga   18
• <210> 300 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 300 ugguaguuga agcaaucu   18
• <210> 301 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 301 uaauguggua guugaagc   18
• <210> 302 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 302 gacauuaaug ugguaguu   18
• <210> 303 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 303 gcucagacau uaaugugg   18
• <210> 304 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 304 ucugagcuca gacauuaa   18
• <210> 305 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 305 gaaccucuga gcucagac   18
• <210> 306 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 306 agaaagaacc ucugagcu   18
• <210> 307 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 307 acuguggaag augauggg   18
• <210> 308 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 308 ccagaacugu ggaagaug   18
• <210> 309 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 309 uuuugccaga acugugga   18
• <210> 310 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 310 aauaauuuug ccagaacu   18
• <210> 311 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 311 uaaauuucuu cugggccu   18
• <210> 312 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 312 acgcuuaaau uucuucug   18
• <210> 313 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 313 auaagacgcu uaaauuuc   18
• <210> 314 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 314 gcagcauaag acgcuuaa   18
• <210> 315 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 315 ccgaugcagc auaagacg   18
• <210> 316 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 316 uuuauccgau gcagcaua   18
• <210> 317 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 317 cccacuuuau ccgaugca   18
• <210> 318 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 318 uucaucccac uuuauccg   18
• <210> 319 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 319 gucuguucau cccacuuu   18
• <210> 320 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 320 uagaugucug uucauccc   18
• <210> 321 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 321 uguguuagau gucuguuc   18
• <210> 322 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 322 cccuuugugu uagauguc   18
• <210> 323 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 323 caucucccuu uguguuag   18
• <210> 324 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 324 aaguuccugg ucaaacac   18
• <210> 325 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 325 gcaucaaguu ccugguca   18
• <210> 326 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 326 ccagugcauc aaguuccu   18
• <210> 327 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 327 aauuuccagu gcaucaag   18
• <210> 328 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 328 gucucaauuu ccagugca   18
• <210> 329 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 329 guacugucuc aauuucca   18
• <210> 330 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 330 cuuuuguacu gucucaau   18
• <210> 331 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 331 gucuccuuuu guacuguc   18
• <210> 332 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 332 ggauugucuc cuuuugua   18
• <210> 333 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 333 gggauggauu gucuccuu   18
• <210> 334 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 334 ucuuauauga cuuucggg   18
• <210> 335 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 335 uucaucuuau augacuuu   18
• <210> 336 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 336 aagaguucau cuuauaug   18
• <210> 337 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 337 acaggaagag uucaucuu   18
• <210> 338 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 338 ucugcacagg aagaguuc   18
• <210> 339 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 339 ggauaucugc acaggaag   18
• <210> 340 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 340 gagcaggaua ucugcaca   18
• <210> 341 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 341 gcaaagagca ggauaucu   18
• <210> 342 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 342 aggaggcaaa gagcagga   18
• <210> 343 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 343 cuuauaggag gcaaagag   18
• <210> 344 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 344 uuccacuuau aggaggca   18
• <210> 345 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 345 agacauucca cuuauagg   18
• <210> 346 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 346 ccgggagaca uuccacuu   18
• <210> 347 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 347 gagggccggg agacauuc   18
• <210> 348 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 348 gcaaugaggg ccgggaga   18
• <210> 349 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 349 agccagcaau gagggccg   18
• <210> 350 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 350 gagucagcca gcaaugag   18
• <210> 351 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 351 gggcuggguc cugaggca   18
• <210> 352 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 352 gccuagggcu ggguccug   18
• <210> 353 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 353 uggcugccua gggcuggg   18
• <210> 354 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 354 uguccuggcu gccuaggg   18
• <210> 355 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 355 gaaagugucc uggcugcc   18
• <210> 356 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 356 aaaacgaaag uguccugg   18
• <210> 357 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 357 acaggaaaac gaaagugu   18
• <210> 358 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 358 gaagaacagg aaaacgaa   18
• <210> 359 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 359 ggcuagaaga acaggaaa   18
• <210> 360 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 360 ugcagggcua gaagaaca   18
• <210> 361 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 361 aaaguugcag ggcuagaa   18
• <210> 362 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 362 uuccuaaagu ugcagggc   18
• <210> 363 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 363 gacaauuccu aaaguugc   18
• <210> 364 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 364 gacaggacaa uuccuaaa   18
• <210> 365 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 365 aggcagacag gacaauuc   18
• <210> 366 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 366 aacaaaggca gacaggac   18
• <210> 367 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 367 uuugaaacaa aggcagac   18
• <210> 368 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 368 ccaaguuuga aacaaagg   18
• <210> 369 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 369 uggcuccaag uuugaaac   18
• <210> 370 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 370 agcacuggcu ccaaguuu   18
• <210> 371 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 371 agcguagcac uggcucca   18
• <210> 372 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 372 cuccaagcgu agcacugg   18
• <210> 373 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 373 acaggcucca agcguagc   18
• <210> 374 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 374 uguugacagg cuccaagc   18
• <210> 375 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 375 aaggguguug acaggcuc   18
• <210> 376 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 376 ugacuaaggg uguugaca   18
• <210> 377 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 377 agaucugacu aagggugu   18
• <210> 378 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 378 ucagcagauc ugacuaag   18
• <210> 379 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 379 gagaaucagc agaucuga   18
• <210> 380 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 380 ccccagagaa ucagcaga   18
• <210> 381 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 381 caggacccca gagaauca   18
• <210> 382 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 382 guugacaggc uccaagcg   18
• <210> 383 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 383 aggguguuga caggcucc   18
• <210> 384 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 384 gacuaagggu guugacag   18
• <210> 385 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 385 gaucugacua aggguguu   18
• <210> 386 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 386 cagcagaucu gacuaagg   18
• <210> 387 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 387 agaaucagca gaucugac   18
• <210> 388 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 388 cccagagaau cagcagau   18
• <210> 389 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 389 aggaccccag agaaucag   18
• <210> 390 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 390 ucagcaggac cccagaga   18
• <210> 391 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 391 ccaggucagc aggacccc   18
• <210> 392 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 392 uuguuccagg ucagcagg   18
• <210> 393 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 393 ccaacuuguu ccagguca   18
• <210> 394 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 394 cuccaccaac uuguucca   18
• <210> 395 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 395 acccacucca ccaacuug   18
• <210> 396 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 396 aucccaccca cuccacca   18
• <210> 397 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 397 aaaccauccc acccacuc   18
• <210> 398 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 398 ucccaaaacc aucccacc   18
• <210> 399 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 399 uuaaauccca aaaccauc 18
• <210> 400 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 400 accacuuaaa ucccaaaa   18
• <210> 401 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 401 ccagaaccac uuaaaucc   18
• <210> 402 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 402 cagaaccaga accacuua   18
• <210> 403 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 403 guccccagaa ccagaacc   18
• <210> 404 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 404 ccaauguccc cagaacca   18
• <210> 405 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 405 cauaaccaau guccccag   18
• <210> 406 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 406 augggcauaa ccaauguc   18
• <210> 407 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 407 aaaccauggg cauaacca   18
• <210> 408 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 408 cuaagaaacc augggcau   18
• <210> 409 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 409 agcuucuaag aaaccaug   18
• <210> 410 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 410 guucaagcuu cuaagaaa   18
• <210> 411 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 411 ggugcugucc aucacauc   18
• <210> 412 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 412 gugguggugc uguccauc   18
• <210> 413 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 413 ucuggguggu ggugcugu   18
• <210> 414 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 414 guauuucugg gugguggu   18
• <210> 415 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 415 auccaguauu ucugggug   18
• <210> 416 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 416 ugucaaucca guauuucu   18
• <210> 417 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 417 cuggauguca auccagua   18
• <210> 418 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 418 cgcaacugga ugucaauc   18
• <210> 419 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 419 cccagcgcaa cuggaugu   18
• <210> 420 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 420 guccccccag cgcaacug   18
• <210> 421 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 421 ucauaguccc cccagcgc   18
• <210> 422 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 422 gggaaucaua gucccccc   18
• <210> 423 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 423 gucgugggaa ucauaguc   18
• <210> 424 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 424 ucaaugucgu gggaauca   18
• <210> 425 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 425 agcgcucaau gucguggg   18
• <210> 426 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 426 ggcguagcgc ucaauguc   18
• <210> 427 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 427 gcccgggcgu agcgcuca   18
• <210> 428 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 428 acuuggcccg ggcguagc   18
• <210> 429 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 429 caggaacuug gcccgggc   18
• <210> 430 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 430 uaguccagga acuuggcc   18
• <210> 431 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 431 ugguguaguc caggaacu   18
• <210> 432 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 432 gucgguggug uaguccag   18
• <210> 433 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 433 auguugucgg ugguguag   18
• <210> 434 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 434 uacucauguu gucggugg   18
• <210> 435 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 435 guagauacuc auguuguc   18
• <210> 436 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 436 gaaggguaga uacucaug   18
• <210> 437 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 437 ugggcgaagg guagauac   18
• <210> 438 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 438 accugugggc gaagggua   18
• <210> 439 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 439 aguacaccug ugggcgaa   18
• <210> 440 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 440 cgaugaguac accugugg   18
• <210> 441 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 441 aauggcgaug aguacacc   18
• <210> 442 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 442 aggucaaugg cgaugagu   18
• <210> 443 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 443 aggccagguc aauggcga   18
• <210> 444 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 444 guuauaggcc aggucaau   18
• <210> 445 <211> 18 <212> RNA <213> Artificial Sequence
• <220> <223> Description of Artificial Sequence: Synthetic oligonucleotide
• <400> 445 ugcaaguuau aggccagg   18
• <210> 446 <211> 474 <212> DNA <213> Homo sapiens
• <400> 446
• <210> 447 <211> 1703 <212> DNA <213> Homo sapiens
• <400> 447
• <210> 448 <211> 645 <212> DNA <213> Homo sapiens
• <400> 448

Claims (12)

1. A pharmaceutical composition comprising an antisense oligomer (ASO) or a viral vector encoding an ASO, wherein the ASO comprises a sequence selected from SEQ ID NOs: 351-353, 355, 357-360, 404, 409 and 410.
2. A pharmaceutical composition according to claim 1 for use in treating Retinitis pigmentosa 13 (RP13) in a subject.
3. A pharmaceutical composition for use in treating Retinitis pigmentosa 13 (RP13) in a subject, wherein the pharmaceutical composition comprises an ASO or a viral vector encoding an ASO, wherein the ASO is complementary to at least 8 contiguous nucleic acids of SEQ ID NO: 448, or of a sequence with at least 90% sequence identity to SEQ ID NO: 448, located within a retained-intron-containing pre-mRNA (RIC pre-mRNA) that encodes PRPF8 protein, and wherein the ASO increases the level of PRPF8 protein expression in the cells.
4. A pharmaceutical composition for use according to claim 3, wherein the targeted portion of the RIC pre-mRNA is within the region +6 relative to the 5' splice site of the retained intron to -16 relative to the 3' splice site of the retained intron.
5. A pharmaceutical composition for use according to any of claims 3 to 4, wherein the RIC pre-mRNA comprises a sequence with at least 80% sequence identity to SEQ ID NO: 4.
6. A pharmaceutical composition for use according to any of claims 3 to 5, wherein the ASO comprises a sequence selected from SEQ ID NOs: 351-353, 355, 357-360, 404, 409 and 410.
7. A pharmaceutical composition according to claim 1 or a pharmaceutical composition for use according to any of claims 2 to 6, wherein the ASO comprises a backbone modification comprising a phosphorothioate linkage or a phosphorodiamidate linkage; or a modified sugar moiety or a sugar analog, optionally comprising a phosphorodiamidate morpholino, a locked nucleic acid, a peptide nucleic acid, a 2'-O-methyl moiety, a 2'-Fluoro moiety, or a 2'-O-methoxyethyl moiety.
8. A pharmaceutical composition according to claim 1 or a pharmaceutical composition for use according to any of claims 2 to 7, wherein the ASO consists of from 8 to 50 nucleobases.
9. A pharmaceutical composition for use according to any of claims 2 to 8, wherein the PRPF8 protein is deficient in amount in the subject to be treated.
10. A pharmaceutical composition for use according to any of claims 2 to 8, wherein the PRPF8 protein is deficient in activity in the subject to be treated.
11. A pharmaceutical composition for use according to any of claims 2 to 10, wherein the PRPF8 protein is deficient in amount or activity in the subject to be treated, and the deficient amount of the PRPF8 protein is caused by haploinsufficiency of the PRPF8 protein, wherein the subject has a first allele encoding a functional PRPF8 protein, and a second allele from which the PRPF8 protein is not produced, or a second allele encoding a nonfunctional PRPF8 protein, and wherein the ASO binds to a targeted portion of a RIC pre-mRNA transcribed from the first allele.
12. A pharmaceutical composition for use according to any of claims 2 to 11, wherein the ASO is administered by intrathecal injection, intracerebroventricular injection, intraperitoneal injection, intramuscular injection, subcutaneous injection, or intravenous injection of the subject.